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New treatment methods are urgently needed for glioblastoma (GBM), the most 
common malignant primary brain tumor in adults, that currently lacks any curative 
treatment. Targeted therapeutic approaches have shown promising results already, 
but common drug delivery vehicles come with efficacy issues and are restricted by their 
safety and toxicity profiles. Exosomes, cell-produced nanosized vesicles, have 
emerged as a new potential carrier for gene therapies in cancer treatment due to their 
natural material transport properties, biocompatibility, and specificity in transporting 
cargo to the target cells. These extracellular vesicles have the additional advantage of 
being able to cross the blood-brain-barrier (BBB), which makes them especially 
valuable for brain malignancies, such as glioblastomas. So far, gene therapy 
approaches in exosomes have focused on RNA in cancer treatment, but research 
findings are limited with plasmid-based gene therapies using exosomes. The main 
concern has been whether the increased plasmid size would decrease the transfection 
efficiency of the plasmid into the exosomes.  
This study aimed at setting-up exosomes as plasmid-based gene therapy 
nanocarriers. To achieve this, different plasmid-based gene therapies were tested, 
including the targeting of common aberrations of GBM cells to impair proliferation and 
the use of cytotoxins to induce apoptosis in the target cells. The plasmids were 
transfected into exosomes and subsequently inoculated into patient-derived 
glioblastoma cells with the aim of decreasing the number of glioblastoma cells.                                                                                                                
The findings of this study demonstrate a successful set-up of an exosome-based gene 
therapy in patient-derived glioblastoma cells by using engineered HEK293FT cell 
derived exosomes consisting of a plasmid-based combination gene therapy encoding 











ADPR   Adenosine diphosphate ribose 
AV   Adenovirus 
BBB   Blood-brain-barrier 
bp   Base pairs 
BSL-2   Biosafety Level 2 
CAFs   Cancer-associated fibroblast 
CDKN2A  Cyclin-dependent kinase inhibitor 2A 
CTLs   Cytotoxic T lymphocytes 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
dNTP   Deoxyribonucleotide triphosphate 
dsDNA    Double stranded DNA  
DT   Diphtheria toxin 
DTA   Diphtheria toxin fragment A 
E. coli   Escherichia coli 
EDTA   Ethylenediaminetetraacetic acid 
EF2   Elongation factor 2 
EGF   Epidermal growth factor 
eGFP   Enhanced green fluorescent protein 
EGFR   Epidermal growth factor receptor 
EGFRvIII  Epidermal growth factor receptor variant III 
EtOH   Ethanol 
FGF   Fibroblast growth factor 
GBM   Glioblastoma 
GFP   Green fluorescent protein 
GzmB   Granzyme B 
HDM2   Human double minute 2  
HEK   Human embryonic kidney 
IDH1   Isocitrate dehydrogenase 1 
IL-8   Interleukin 8 
IT   Immunotoxins 
kb   kilobase 
LB medium  Lysogeny broth 
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MDM2   Mouse double minute 2 homolog 
MEM α   Minimum Essential Medium α 
MET    Mesenchymal epithelial transition factor   
MGMT   O[6]-methylguanine-DNA methyltransferase 
miRNA   Micro ribonucleic acid 
mQ   MilliQ 
MRI   Magnetic resonance imaging 
mRNA   Messenger ribonucleic acid  
NAD   Nicotinamide adenine dinucleotide 
NK   Natural killer 
NLuc   NanoLuc 
PBS   Phosphate-buffered saline 
PCR   Polymerase chain reaction 
PDGF-A  Platelet-derived growth factor A 
PDGFRA  Platelet-derived growth factor receptor A 
PI3K   Phosphoinositide 3-Kinase 
PIP3   Phosphatidylinositol-3,4,5-trisphosphate 
PTEN   Phosphatase and Tensin homolog 
RAS   Rat sarcoma  
RB1   Retinoblastoma gene 
RNA   Ribonucleic acid 
SEC   Size Exclusion Chromatography 
siRNA   Small interfering ribonucleic acid 
TAE   Tris acetate EDTA  
TCC   Transitional cell carcinoma  
TKR   Tyrosine kinase receptor   
VEGF   Vascular endothelial growth factor 












1.1 Glioblastoma  
 
Glioblastoma, which is classified as a grade IV glioma by the World Health 
Organization (WHO) and arises from progenitor or neuroglial stem cells (Tang et al., 
2019), is the most lethal form of cancer in humans (Mrugala, 2013) and the most 
severe and common primary tumor within the brain in adults (Wirsching et al., 2016). 
The World Health Organization classified glioblastoma as a grade IV diffuse astrocytic 
and oligodendroglial tumor with a yearly incidence of 0.59 to 5 per 100,000 persons 
(Grech et al., 2020). A slight increase of the incidence in the last 20 years has been 
noted, which can be explained with an improvement in radiologic diagnosis and with a 
rising incidence in older patients (Alifieris & Trafalis, 2015).  
The incidence for men is increased 1.6 times compared to the incidence for women 
and the risk for Caucasians has been reported 2.0 times higher than the risk for Afro-
Americans and Africans, with Asians and American Indians showing a lower incidence 
(Tamimi & Juweid, 2017). While glioblastoma can develop at any age (Hanif et al., 
2017), the mean age when glioblastoma occurs is 62 years (Grech et al., 2020). The 
average survival of the glioblastoma patients following diagnosis is 14 to 15 months 
(Hanif et al., 2017), emphasizing the need for new efficient therapies.  
The symptoms of glioblastoma depend on many factors such as the region of the brain 
that is affected, the tumor size, the location of the tumor and secondary effects, 
including a rise in intracranial pressure. The symptoms vary from seizures, focal neural 
deficits, cognitive impairment to changes in behavior, balance issues and headaches, 
which are especially common and present in 30 – 50% of glioblastoma patients (Hanif 
et al., 2017).  
The research for risk factors in the development of glioblastoma is ongoing but so far 
solely radiation and certain genetic syndromes were identified as causes for GBM, 
while environmental factors, including an unhealthy diet, mobile phones, exposure to 
pesticide or smoking were found not to be associated with glioblastoma (Hanif et al., 
2017). As of now, there is no known method of preventing the development of 
glioblastoma (Gallego, 2015).  
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The pathogenesis of glioblastoma has been a consistent topic of research to develop 
new therapies and an understanding of the tumor resistance. This disease is 
characterized by necrosis, angiogenesis, genomic aberrations, infiltration, uninhibited 
cell proliferation and apoptosis resistance (Kesari, 2011). Overall, there are two clinical 
forms that have been described for GBM, the primary and secondary glioblastoma. 
95% of patients present with the primary GBM, which arises de novo in a span of 3 to 
6 months and is mostly seen in elderly. Meanwhile secondary GBM presents in 
younger patients and develops from previous low-grade astrocytoma. For both forms, 
the same pathways are altered and the response to treatment does not differ much. 
The epidermal growth factor receptor (EGFR) is often amplified and mutated in primary 
GBM, encoding an altered EGFR, called epidermal growth factor receptor variant III 
(EGFRvIII), while an increase in signaling through the platelet-derived growth factor A 
(PDGF-A) receptor has been discovered in secondary GBM. Both mutations result in 
an increase of the activity of the tyrosine kinase receptors (TKR) and in consequence 
activates the rat sarcoma (RAS) and phosphoinositide 3-Kinase (PI3K) pathways. The 
prevalent mutations in primary GBM have been found in the mouse double minute 2 
homolog (MDM2) gene, encoding for a p53 inhibitor, the homozygous deletions of 
cyclin-dependent kinase inhibitor 2A (CDKN2A) and additionally, mutations of 
phosphatase and tensin homolog (PTEN), whereas p53 mutations, an amplification of 
mesenchymal epithelial transition factor (MET), platelet-derived growth factor receptor 
A (PDGFRA) overexpression and mutations of isocitrate dehydrogenase 1 (IDH1) have 
been connected to secondary GBM. Furthermore, a rise in activity of human double 
minute 2 (HDM2) and the inactivation of the retinoblastoma gene (RB1) have shown 
an association to low-grade gliomas progressing to high-grade gliomas and result in 
altered signaling pathways, which are mediated by growth factors and a change in cell 
cycle regulation. This results in apoptosis inhibition, angiogenesis, invasion and an 
increase in cell proliferation (Alifieris & Trafalis, 2015).  
The diagnosis of glioblastoma is usually done by a magnetic resonance imaging (MRI) 
scan, which is followed by a biopsy of brain tissue. These techniques are performed if 
patients present with symptoms that raise suspicion, such as headaches, nausea, 
cognitive impairment and motor weakness (Batash et al., 2017).   
Worldwide, there has been a considerable amount of research for the treatment of 
glioblastoma (Mrugala, 2013) and yet the prognosis for GBM remains poor with the 
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majority of treatments being palliative (Kesari, 2011). Even though molecular pathways 
responsible for the invasive nature of glioma continue to be found, GBM is still named 
as one of the major challenges in clinical oncology, which is also due to the slow 
translation of the basic research in the laboratory to the clinic and the patients. Over 
the recent years, varying methods of treating glioblastoma have been studied with little 
success. The reasons for this include the heterogeneous biology and a diffuse nature 
of the GBM growth (Mrugala, 2013). Currently, the standard of care of glioblastoma is 
defined by a multimodal approach, which consists of radiation, chemotherapy and 
surgical resection (M. E. Davis, 2016). The concept of treating GBM for newly 
diagnosed patients consists of maximal surgical resection of the tumor prior to radiation 
therapy with simultaneous systemic chemotherapy utilizing the alkylating compound 
temozolomide (Mrugala, 2013), which is the norm for the first-line treatment (Gallego, 
2015). Patients with a methylated O[6]-methylguanine-DNA methyltransferase 
(MGMT) promoter have been connected to an increase in the sensitivity to the drug 
temozolomide, resulting in longer survival compared to the patients with an 
unmethylated MGMT promoter. The methylation status of the promoter can be tested 
by performing a DNA test on the glioblastoma cells (Martinez et al., 2007). Additional 
treatment consists of treating symptoms such as cerebral edema, fatigue and 
infections (Alifieris & Trafalis, 2015). One of the defining issues of the GBM treatment 
is that not all the tumor cells will be removed due to the highly invasive nature of 
glioblastoma cells, which spread over white matter and blood vessels. Therefore, a 
complete resection is not possible. Additionally, the self-renewal of the tumor cells and 
the resistance to radiation and chemotherapy is benefited by a disseminating tumor 
stem-cell like cell population, resulting in the recurrent nature of glioblastoma and 
overall a worse prognosis for long-term survival (Kwiatkowska et al., 2013). Standard 
treatment options, such as surgery are often inefficient since the tumor is scattered 
and cannot be removed completely without harming the brain. In addition, patients with 
tumors in the basal ganglia, brain stem or eloquent cortex are not responsive to surgery 
and consequently display a worse prognosis. Chemotherapy treatment is connected 
to certain limitations as well. Mostly because of numerous chemotherapeutics not 
being able to get past the blood-brain barrier, resulting in serious diminishment of the 
drug delivery to the parenchyma of the brain and the tumor. Additionally, glioblastoma 
shows resistance to chemotherapy due to a hypoxic tumor environment. Due to all 
these reasons, it is not possible to have a universal treatment approach for all 
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glioblastoma patients, but instead multi-targeted therapy is needed (Mrugala, 2013), 
with the treatment being dependent on the onset of the disease, the patient age, the 
time of diagnosis and if the tumor is recurrent (Alifieris & Trafalis, 2015). The progress 
in surgical intervention, chemotherapy and radiotherapy improve the survival of 
patients with glioblastoma and contribute to a higher quality of life (Mrugala, 2013), but 
so far, the disease will recur in the large majority of patients (Gallego, 2015).  
Overall, glioblastoma is one of the human cancers that show the worst 5-year survival 
rates of 4-5% and solely 26-33% of the patients survive beyond two years in clinical 
trials, proving once more that the current treatments only serve as an extension of the 
overall survival and not as a cure for glioblastoma patients. Present treatment 
limitations, GBM´s diffuse nature, advanced age of onset and a limited comprehension 
of the pathophysiology of glioblastoma can be named as reasons for the general brief 
survival span (Batash et al., 2017). However, there is hope for new treatment methods, 
including targeted therapies, which became available due to the discoveries in the 
recent years about the tumor biology of glioblastoma (Kesari, 2011).  
1.2 Gene therapy in glioblastoma cells 
 
With the aim of prolonging overall survival of glioblastoma patients and the limited 
treatment options that are available at this point, it is obvious that new efficient therapy 
approaches are urgently needed as an alternative or complement to present treatment 
plans. Gene therapy, which molecularly targets the tumor and its surrounding 
microenvironment has emerged as a potential new treatment for glioblastoma. While 
gene therapy has originally been designed to mostly improve and treat genetic 
diseases that occurred due to the deficiency of a single gene, the main approach for 
gene therapy in cancer has been focused on delivering therapeutic genetic material to 
the tumor cells in order to eradicate cancer cells or alternatively amend the response 
of the immune system against the cancer cells (Kwiatkowska et al., 2013) 
So far gene therapy has been focused on mRNA-based therapeutic models, 
advantages of which consist of fast and temporary expression, flexible convertibility, 
and simple manipulation. All these advantages make it possible to handle the variable 
and complex nature of glioblastoma and thus synthetic anticancer mRNAs taken up by 
diverse delivery vehicles have been shown to succeed in crossing biological barriers 
and attacking the tumor cells (Tang et al., 2019).  
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Several main gene therapy approaches have been developed in the past years, with 
the main ones focusing on the delivery of cytokine genes to enhance the immune 
response, the delivery of suicide genes with the aim of apoptosis induction in the tumor 
cells, the delivery of viruses, that show a conditional replication and result in the lysis 
of cancer cells without harming healthy tissue and the transfer of tumor-suppressor 
genes to tumor cells, which leads to reprogramming of the cancer cells into 
programmed cell death. Many of these strategies have shown success in pre-clinical 
models and in recent years, a constant rise in the amount of gene therapy models in 
clinical trials could be noted (Kwiatkowska et al., 2013). However, delivery of the 
therapeutic genes into cancer cells could only be detected within a close distance from 
the delivery site, which has been one of the limiting factors of success in clinical trials 
(Clarke et al., 2010). Viruses have been shown to be the main delivery vehicles for the 
gene therapy but there are alternative carriers, including nanoparticles, liposomes, and 
stem cells, which can be utilized for the delivery of the genetic material to the cancer 
cells (Kwiatkowska et al., 2013).  
1.2.1 Targeting plasmids for common genetic alterations in glioblastoma cells 
 
Cancer cells derive from normal cells by developing mutations in key genes, such as 
tumor suppressor genes or oncogenes (G. Castro et al., 2011). Tumorigenesis in 
humans develops over multiple steps with each step involving genetic alterations 
driving the continuous transformation of healthy cells into malignant derivatives 
(Hanahan & Weinberg, 2000). The altered genes are responsible for important cellular 
processes, including apoptosis and proliferation. Numerous mutations in genes in 
charge of angiogenesis, cell cycle progression, rising motility and growth factor 
independence need to accumulate to result in tumorigenesis. The main characteristics 
of gliomagenesis are known and consequently gene therapy has been developed with 
a focus on repairing common genetic aberrations in glioblastoma cells  (G. Castro et 
al., 2011).   
1.2.1.1 Inhibition of oncogene EGFRvIII 
 
Epidermal growth factor receptor has been shown to promote growth of glioblastoma 
cells by activating the intracellular tyrosine kinase domain through the binding of its 
ligand, epidermal growth factor (EGF) to the extracellular part to initiate various 
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signaling cascades. The signaling activity of EGFR, which is frequently caused by 
mutations, such as EGFRvIII, is often abnormally elevated in glioblastoma cells. This 
specific mutation is caused by an in-frame deletion of exons 2 to 7 and can exist without 
an amplification of EGFR (Padfield et al., 2015). This deletion in the extracellular 
binding domain, which has been shown to be part of approximately 40% of GBMs, 
leads to a constitutively active tyrosine kinase domain (Clarke et al., 2010). EGFRvIII 
is the most important variant among the mutations of EGFR (Bălașa et al., 2020) and 
is connected with an increase in the proliferation of glioma cells (Montano et al., 2011) 
and results in resistance to chemotherapy and apoptotic stimuli (Bălașa et al., 2020). 
Consequently, the primary part of my MSc thesis project´s gene therapy approach 
includes a plasmid containing inhibitory RNA molecules, downregulating the 
expression of the EGFRvIII target gene. 
1.2.1.2 Overexpression of tumor suppressor gene TP53 
 
The tumor suppressor gene TP53 is the guardian of the genome and its main function 
includes detecting genetic abnormalities, that occur in the process of DNA synthesis. 
Following the detection of a genetic abnormality, the cell cycle progression is stopped, 
and the repair process is observed. In case of a significant damage to the DNA, 
apoptosis is induced by the p53 protein encoded by the TP53 gene. Quiescent cells 
do not show any p53 expression, yet expression is seen in cells undergoing cell cycle 
progression and as a result of DNA damages (G. Castro et al., 2011). Consequently, 
this tumor suppressor gene is a vital part of the reduction of tumor development and it 
is either carrying mutations or missing in more than half of human tumors, while 
mutations in parts of the p53 pathway have been detected in 90% of all human tumors 
(G. Castro et al., 2011). Additionally, in glioblastoma, deregulated parts of the p53 
pathway have been suspected as part of cancer cell stemness, proliferation, cell 
invasion, migration, proliferation, and apoptosis evasion. Overall, TP53 is among the 
most frequently deregulated genes in cancer cells and a deregulation of the p53 
pathway occurs in 94 percent of GBM cell lines and in more than 4 out of 5 patients 
with glioblastoma (Y. Zhang et al., 2018). Consequently, the first part of the gene 
therapy in this research project focuses on overexpressing the TP53 gene in order to 
support tumor suppression in glioblastoma cells.  
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1.2.1.3 Overexpression of tumor suppressor gene PTEN 
 
PTEN (phosphatase and tensin homolog) is defined as a phosphatidylinositol-3,4,5-
trisphosphate (PIP3) phosphatase and plays a crucial role in tumor suppression by 
antagonizing the oncogenic PI3-kinase signaling pathway (Yang et al., 2017). The 
PI3K/AKT/mTOR pathway is part of the primary molecular pathways responsible for 
the expansion of glioblastoma cells and normally inhibited by PTEN and thus a 
mutation of PTEN promotes severe proliferation of the cancer cells (Bălașa et al., 
2020). In glioblastoma, the tumor suppressor gene PTEN is frequently mutated or 
deleted, which results in a resistance to therapy. Moreover, it has been shown that 
mutations that result in reduced protein function in PTEN are associated with a 
deficient response to chemotherapy and radiation therapy treatment in brain cancer 
patients and in addition display a connection to metastasis. This demonstrates the role 
of PTEN as a central regulator of tumor sensitivity to a variety of treatments (Benitez 
et al., 2017). Therefore, overexpression of PTEN is part of the first approach of the 
plasmid-based gene therapy, that has been conducted in this project.  
1.2.2 Targeting plasmids utilizing apoptosis-inducing Granzyme B enzyme 
 
Targeted therapy could avoid the disadvantages that often come with conventional 
treatments in cancer patients, such as an insufficient specificity and serious side 
effects. One of the approaches in targeted therapy consists of immunotoxins (ITs), 
which include cell-binding and apoptosis-inducing components delivered directly to 
malignant cells. Granzyme B is an enzyme that has proven to be a promising candidate 
for targeted therapy in cancer cells (Hehmann-Titt et al., 2013).  
Granzyme B (GzmB) is defined as a serine protease and part of secretory granules of 
cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. CTLs and NK cells utilize 
granzyme B to induce apoptosis as their primary mechanism of action to eradicate 
targets such as cancer cells. Granzyme B and additional granule proteins such as 
perforin are secreted into the immunological synapse by the engaged natural killer cells 
and cytotoxic T lymphocytes following the detection of the target cells. Subsequently, 
Granzyme B is translocated into the target cell´s cytoplasm, in which several protein 
substrates are cleaved and activated or inactivated by the protein, leading to the target 
cell´s apoptosis (Rousalova & Krepela, 2010).  
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In this research project, Granzyme B was selected as one of the potential candidates 
for the plasmid-based gene therapy to induce apoptosis in glioblastoma cells.   
1.2.3 Targeting plasmid utilizing apoptosis-inducing Diphtheria toxin fragment A  
 
Diphtheria toxin (DT) is one of the main cytolethal toxins used in the construction of 
immunotoxins targeted cancer therapy (Chandramohan et al., 2012) focusing on gene 
delivery and cell-specific toxin expression (Shafiee et al., 2019). One molecule of toxin 
will result in an irreversible inactivation of 300 ribosomes in 35 minutes, thereby 
efficiently killing tumor cells (Chandramohan et al., 2012). Diphtheria toxin, a single 
chain 62 kDa protein, includes 535 amino acid residues and inhibits protein synthesis 
in susceptible cells, thereby being cytotoxic (Shafiee et al., 2019). The toxin consists 
of two regions, the 21-kDa fragment A (J. Zhang et al., 2012), located at the N-terminus 
contains a catalytic domain, and is responsible for halting the protein synthesis in 
eukaryotic cells (Shafiee et al., 2019), by inactivating the elongation factor 2 (EF2) (J. 
Zhang et al., 2012). The second fragment defined as fragment B, is located at the C-
terminus and includes a transmembrane domain and a domain for receptor binding 
(Shafiee et al., 2019). The 37-kDa fragment B is responsible for delivering the A 
fragment (DTA) into cells by attaching to receptors on the cell surface (J. Zhang et al., 
2012). The protein synthesis is inhibited by the binding of the catalytic domain to 
nicotinamide adenine dinucleotide (NAD) in the cell´s cytoplasm, followed by 
translocation of an adenosine diphosphate ribosyl (ADPR) moiety to EF2, hereby 
inactivating it (Shafiee et al., 2019). The DTA protein is highly toxic and has been 
commonly used in targeted tumor therapy to eradicate cancer cells (J. Zhang et al., 
2012). 
Due to its toxicity and proven efficiency as cancer therapy, Diphtheria toxin fragment 
A was selected as a potential candidate for the project´s plasmid-based gene therapy 
to induce apoptosis in glioblastoma cells.   
1.3 Exosomes as potential new delivery vehicle for gene therapy 
 
So far, gene therapy has focused mostly on plasmids, viral vectors, cosmids and 
artificial chromosomes as the four major vector types. However, those options suffer 
from some disadvantages. Viral vectors are connected with serious safety concerns, 
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while the production of non-viral DNA vectors is limited by a low transfection efficiency 
and a potential mutation induction (Tang et al., 2019).  
In recent years, exosomes have come into the research focus as potential tumor 
targeted vehicles to transport therapeutic molecules directly to tumor cells. Exosomes 
are secreted and subsequently naturally taken up by cells and have shown the ability 
to steadily translocate pharmaceutical compounds, proteins, and therapeutic 
microRNAs. Since the cargo of exosomes includes genetic material, this can be taken 
advantage of by developing exosomal therapy utilizing microRNAs. MicroRNAs 
(miRNAs) are small-sized, non-coding RNAs, known to bind to the 3´-untranslated 
region of mRNAs and subsequently silencing or degrading the target RNA, hereby 
inhibiting translation and thereby the protein synthesis (Gilligan & Dwyer, 2017). In the 
treatment of breast, pancreatic, prostate, lung cancer and glioblastoma, exosomes 
have been used for the delivery of conventional chemotherapeutics, natural products 
and RNA (Pullan et al., 2019).  
While so far, the focus has been on small interfering RNA (siRNA) and miRNA in 
exosome-based gene therapies for the treatment of varying diseases (Orefice, 2020), 
this research project focuses on using an exosome-based gene therapy, which utilizes 
a plasmid-based therapeutic model. So far, no in-depth research is available for the 
use of exogenous plasmid DNA in extracellular vesicles (Orefice, 2020).  
1.3.1 Characteristics of exosomes 
 
Exosomes are defined as a subtype of extracellular vesicles, which are released by 
varying cell types and contain components such as proteins, RNA, lipids, metabolites, 
or DNA. They can be taken up by other cells, potentially leading to changes in cell 
behavior and function (Kalluri & LeBleu, 2020). Exosomes originate from multivesicular 
bodies, which are defined as intraluminal vesicles of late endosomal compartments 
and these endosomes fuse with the cell membrane, thereby allowing the vesicles to 
be released into the extracellular compartment. In addition, extracellular  stimuli or 
certain elements, resulting in stress, may positively influence their generation (De Toro 
et al., 2015). The nanosized extracellular vesicles are part of intercellular 
communication in normal as well as in pathological conditions (Sharma et al., 2016) 
and do so by trafficking molecules between cells (Srivastava et al., 2015). Moreover, 
exosomes contain cell-of-origin biomacromolecules and thus reflect the cell's 
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molecular bioprint (Sharma et al., 2016). In addition, exosomes are known to contain 
active genetic information in their lumen such as DNA, miRNA, mRNA and active 
peptides, which are characteristic for the parental cell and various fluids in the human 
body can be utilized for the isolation of these genetic components. Due to the ability of 
exosomes to translocate components from one cell to another while being able to cross 
biological barriers such as the blood-brain barrier, without triggering the immune 
system, these extracellular vesicles have been developed as novel acellular carriers 
for pharmaceutical compounds (Srivastava et al., 2015). 
1.3.2 Exosomes in cancer – friend or foe?  
 
Exosomes play a dual role in cancer therapy. On one side, the extracellular vesicles 
have been associated to varying hallmarks of cancer by impacting neoplasia, 
metastasis, the growth of tumors and resistance to several chemotherapeutic agents 
and antibodies (Kalluri & LeBleu, 2020). In the essential step of growth and spreading 
of the tumor, exosomes have been associated with the tumor angiogenesis and 
extracellular matrix transformation (Kalluri & LeBleu, 2020). Additional research has 
shown that exosomes play a crucial role in metastasis by travelling to distant organs 
and promoting the formation of a pre-metastatic niche by interacting with the stromal 
cells (Bastos et al., 2018). Further, exosomes are able to interact directly with 
therapies, hereby reducing their efficiency against the tumor cells. In addition, 
exosomes, secreted from cancer-associated fibroblasts (CAFs) are capable of altering 
the cancer cell´s transcriptome to support the tumor cell´s survival (Kalluri & LeBleu, 
2020). Moreover, exosomes secreted from cancer cells contain an elevated amount of 
vascular endothelial growth factor (VEGF) and interleukin 8 (IL-8), which promotes the 
induction of neovascularization, a process essential for the formation of vessels. The 
invasion of tumors is facilitated by cancer exosome’s ability to support matrix 
remodeling and enhance the expression of matrix metalloproteinase in fibroblasts. 
Furthermore, the extracellular vesicles promote an environment, which is prone to the 
development of tumors due to the promotion of the immune escape of tumor cells by 
regulating the activity of immune cells. These findings stress the importance of studying 
the potential of targeting the exosome-mediated communication as a treatment 
approach in cancer therapy. Another research focus has been the targeting of 
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exosomes with the aim of blocking their support function in the progression of tumors 
and therapy resistance (Bastos et al., 2018).  
However, exosomes have shown promising potential in improving cancer therapy as 
well, by being applicable as carriers of anti-cancer molecules due to their stability in 
circulation, their ability to directly target tumors and their intrinsic capability of 
horizontally transferring cargo. In cancer and other diseases, exosomes are 
investigated as new delivery vehicles for drugs due to their natural presence in body 
fluids and their biocompatibility and biodegradable nature. As a consequence of this, 
exosomes have been shown to have reduced toxicity and to be less immunogenic 
when compared to other nanocarriers. Overall, exosomes show promising potential to 
enhance the efficiency of cancer treatment by functioning as delivery vehicles for 
therapeutic drugs, antibodies or RNA for the manipulation of gene expression (Bastos 
et al., 2018).  
1.3.3 Disadvantages of current standard delivery vehicles  
 
Gene therapy has become a promising field in the development of cancer treatment.  
The common vectors in gene therapy can be divided into viral and non-viral vectors. 
Though until now, there are several restricting factors responsible for limited success 
of gene therapies in treating cancer. So far, issues such as limited transfection 
efficiency of the gene, the precise delivery of the target gene to the target site and the 
avoidance of toxicity and severe side effects have to be addressed to increase the 
performance of gene therapies in cancer treatment (Sun et al., 2014). While viral 
vectors have emerged as the main delivery vehicle of DNA and RNA in gene therapy 
on account of their transduction efficiency, several problems have appeared. These 
include serious immune responses and the issue of adenoviral (AV) vectors, which 
following systemic administration, remain in the liver, thereby compromising the 
efficiency of the transgene transduction, resulting in hepatotoxicity and death (Orefice, 
2020).  
Overall, current delivery vehicles are restricted by safety and toxicity concerns, and 
limited efficiency.  




Plasmid-based gene therapies are associated with several advantages, which make 
them interesting for cancer therapy when compared to the RNA-based gene therapies. 
Due to the plasmids modular composition, straightforward molecular cloning is 
possible, resulting in many potential actions, such as manipulation and design of 
plasmids for new therapeutic approaches (Hardee et al., 2017).  By being able to 
perform molecular cloning to design the plasmids, it further encourages finetuning and 
enhancing steps, which can be carried out to increase the targeting efficiency of the 
plasmid-based gene therapy. In addition, conditional expression, which is defined by 
specifically expressing the gene therapy in a certain type of cell or certain time, 
becomes an option. This project uses mir21 and IL13RA2 promoters, to enhance the 
specificity of the therapy and further reduce cytotoxic effects in case the exosomes 
target healthy cells. The plasmid-based gene therapy will mostly be active in cancer 
cells, since the expression of Mir21 and IL13RA2 is substantially upregulated in cancer 
cells, compared to the healthy cells.  
Exosomes are defined as natural cell-produced nanosized delivery vesicle and have 
been shown to be immunologically inert when isolated from compatible cells and 
further display an inherent capacity to pass inflexible barriers in the human body 
(O’Loughlin et al., 2012), making them a novel promising delivery vehicle for gene 
therapy.  
In this therapeutic set-up, exosomes were chosen as the delivery vehicles for gene 
therapy due to several reasons. These include their numerous advantages as carriers, 
due to their properties, such as their physical characteristics, including biocompatibility, 
permeability, minor toxicity, low immunogenicity, and stability. Thus, exosomes are an 
exceptional material platform, which contains all the features indispensable for 
successful outcome of any nanoparticle drug delivery system (Pullan et al., 2019). In 
detail, exosomes have been shown to be steady carriers of therapeutic agents, 
demonstrated the ability of potential modifications to enhance cell specific homing and 
deliver therapies directly into the target cells by fusing with the cell´s plasma 
membrane. Allogenic exosomes, which are derived from mesenchymal stem cells, 
potentially resolve the major challenge of cell-based therapies by enabling reduction 
in the immune response. Due to their small size, exosomes can pass barriers, that are 
not possible to cross for cells (Gilligan & Dwyer, 2017). Furthermore, exosomes show 
great promise as carriers for various components due to their ability to translocate 
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natural material and the intrinsic potential for long-term circulation, which is ideal for 
transporting a wide range of components, such as DNA, RNA, proteins and therapeutic 
agents (Liu & Su, 2019). Another reason why exosomes have been studied as natural 
vehicles for the delivery of drugs is due to their ability to move safely in extracellular 
fluids and efficiently and specifically carry cargo to destined cells (Li et al., 2019). 
Exosomes further carry the advantage of being able to house lipophilic as well as 
hydrophobic drugs due to their lipid bilayer membrane holding an aqueous core 
(Gourlay et al., 2017). Moreover, the efficiency of exosome-mediated strategies has 
been shown by the first proof-of-concept studies and in a variety of clinical trials in 
which exosomes have been well-tolerated by the patients, even after prolonged 
administration. In addition, clinical trials for cancer patients demonstrate the safety and 
promise of wide-ranging therapeutic implementations that may benefit from this 
nanotechnology (O’Loughlin et al., 2012). 
Overall, exosomes have opened the door to many opportunities in the therapeutic 
setting due to the possibility of engineering the content of exosomes and their migratory 
itinerary as well as the relatively simple method of isolating exosomes (Gilligan & 
Dwyer, 2017). In addition, the plasmid-based gene therapies allow the regulation and 
finetuning of the plasmid expression in the target cells.  
1.3.5 Exosomes in glioblastoma 
 
Glioblastoma cells have been shown to secrete multiple exosomes, carrying 
components, which have the potential to enhance the tolerance of the immune system 
towards the tumor cells, stimulate chemotherapy resistance, increase the vascular 
supply in glioblastoma, encourage the development from healthy cells to tumor cells, 
and aid in the migration of the cancer cells and the subsequent invasion (Bălașa et al., 
2020), proving that exosomes play a crucial role in the progression of GBM tumors. 
However, exosomes are a new approach in cancer treatment and because of their 
ability to pass the blood-brain-barrier, they are a potential new way of treating 
malignancies in the brain. Compared to liposomes of equal size, these extracellular 
vesicles have tenfold increased capacity to target cancer cells. This may be due to a 
specific interaction of the ligand and receptor on the target cell or enhanced 
endocytosis mechanism. Additionally, the production and engineering of exosomes 
17 
 
can be done in vitro with the possibility of adding specific ligands, resulting in an 
enhanced targeting of tumor cells (Bastos et al., 2018).  
Interestingly, radiation therapy could be utilized as a pre-treatment for enhancing the 
exosome-based therapy uptake in cancer treatment, since radiotherapy has been 
shown to increase the amount of cancer exosomes, secreted by the cells and their 
microenvironment (Bălașa et al., 2020). In glioblastoma, radiation treatment, results in 
a rise of the exosome abundance, secreted by GBM cells and the surrounding normal 
astrocytes. In addition, due to the radiotherapy, the extracellular vesicles have been 
shown to be taken up by acceptor cells more easily (Gourlay et al., 2017). 
In this current time of molecular modification, exosomes display their worth as 
instruments to target glioblastoma cells as part of therapeutic strategies in addition to 
being used as markers for diagnosis and prognosis in cancer (Bălașa et al., 2020). 
1.3.6 Exosome-based gene therapy in glioblastoma cells 
 
Expeditious developments in cancer science, involving the discovery of cellular 
processes and surface antigens that are specific to cancer, have made it possible to 
combine rational drug design and cancer biology to create new targeted therapeutic 
approaches (Shafiee et al., 2019). In the past few years, exosomes have become 
valuable potential instruments to combat the aggressive nature of glioblastoma on 
account of their structure and ability to transport various cargo, with the aim of 
producing individual therapeutic approaches that specifically target the cancer cells 
(Bălașa et al., 2020). Recent studies have shown that exosomes, secreted by brain 
endothelial cells succeeded in delivering pharmacological drugs across the blood-
brain-barrier followed by a decrease of tumor progression. Meanwhile, the drugs, 
administered without exosome vectors failed in crossing the blood-brain-barrier and 
stayed within the vascular circulation. These finding confirm that exosome-based 
therapy opens the door to new possibilities for the treatment of brain tumors by 
succeeding in delivering anti-tumor agents across the blood-brain barrier, a barrier 
which so far has been mostly impenetrable for the majority of chemotherapy agents 
(Gourlay et al., 2017).   
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Overall, it can be seen that exosomes are breaking down the barriers that have been 
set with most of the polymeric drug delivery systems, proving to be viable carriers with 
only minimal toxicity issues and verified biocompatibility (Gourlay et al., 2017).  
1.3.6.1 Selection of HEK293FT cell line as exosome source 
 
So far, many studies have focused on exosomes secreted by tumor cells in cancer 
therapy. However, there are safety concerns due to the role of exosomes in cancer 
progression and possibility of potential problematic effects as a consequence of a gene 
therapy utilizing tumor-derived exosomes (Gilligan & Dwyer, 2017).  
Therefore, exosomes secreted by the HEK293FT cells were selected for this project. 
HEK293FT cells were chosen as the exosome source due to high productivity of the 
biogenesis and secretion of exosomes. In addition, HEK293FT exosomes are very 
commonly available cells (Lin et al., 2018).   
1.3.6.2 Selection of virus transfected OP9 cells as alternative exosome source 
 
The murine mesenchymal progenitor cell line OP9 was used as an alternative source 
of exosomes since exosomes derived from mesenchymal stem cells have shown 
potential as novel instruments in basic research with an indicated effect on the targeted 
delivery of microRNAs in cancer treatment (Wei et al., 2021).  
For this purpose, the cells were transduced with a lentivirus, resulting in exosomes, 
which are expressing the homing peptide iRGD. This homing peptide is known for 
targeting and penetrating tumors by binding to αv integrins and neuropilin-1 receptors, 
expression of which is often elevated on the surface of cancer cells (Yin et al., 2017).  
The tumor targeting peptide works through the RGD motif facilitating the binding to αv 
integrins on the endothelium of the tumor. Subsequently, neuropilin-1 binds to a motif 
exposed due to a proteolytic cleavage, resulting in tissue and cell penetration. The 
homing peptide iRGD thereby increases the activity of drugs targeting the tumor 
(Sugahara et al., 2009). Consequently, iRGD allows delivery of anticancer drugs to the 
tumor parenchyma. Usually there is either a chemical linkage of the peptide and the 
anti-tumor drug or the peptide and the therapy are co-injected (Yin et al., 2017).  
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1.4 Aim of the project 
 
The aim of this research project was to set up an exosome-based gene therapy in 
patient-derived glioblastoma cells utilizing exosomes isolated either from the 
HEK293FT or from virus transfected OP9 cells. Three different gene therapy 
approaches were aimed to be tested to decrease the cell proliferation of the target 
cells. The first one targets common alterations in glioblastoma cells, while the other 
gene therapy approaches focus on using cytotoxins with the goal of inducing apoptosis 
in the cancer cells. While, the mRNA-based gene therapies have shown great potential 
in glioblastoma treatment (Tang et al., 2019), this study focuses on plasmid-based 
gene therapy. Our thinking is that a clear advantage of the plasmid-based therapy is 
that plasmid DNA is an independent, circular vector, encoding for genes of interest 
(Orefice, 2020), thereby allowing finetuning of the expression in the glioblastoma cells. 
Currently, the use of plasmids in exosome-based therapies is an ongoing discussion 
topic in research due to the limited size of exosomes, which makes it questionable if 
exosomes manage to take up the plasmids (Orefice, 2020). This issue will be tried to 
solve through reduction of the plasmid size by cloning the plasmids into miniplasmids, 
followed by a chemical transfection into the exosomes. This approach is supported by 
studies, which showed a correlation between a decrease in plasmid size and an 
improvement in the transfection efficiency (Hardee et al., 2017). 
Setting up a successful plasmid-based gene therapy in exosomes would present a new 
way of controlling gene expression in glioblastoma cells using exosomes as delivery 
vehicles, thereby leading the way towards the generation of exosome-based gene 










2 Material and Methods 
 
2.1 Molecular cloning & bacterial methods  
2.1.1 Gibson Assembly 
The Gibson Assembly Master mix (New England Biolabs 2021, Gibson Assembly®) 
combines 5´exonuclease, DNA ligase and DNA polymerase in a reaction carried out 
in a single tube. First the 5´ exonuclease leads to an opening of the complementary 
sequences for annealing by removing the 5´end sequences. The DNA polymerase 
then synthesizes DNA, to fill the gaps of the annealed single strand regions and in the 
last step, the nick is sealed and a link between the DNA fragments is formed. The 
Gibson Assembly method was used for the cloning of the plasmid constructs. The 
reaction including the following components is performed on ice. The composition of 
the Gibson Assembly reaction is displayed in Table 1. 
Table 1. Composition of the Gibson Assembly reaction (New England Biolabs 2021, Gibson 
Assembly®). 
 2 – 3 Fragment Assembly  
Total Amount of 
Fragments  
0.02 – 0.5 pmols*X μl  
Gibson Assembly Master 
Mix (2X), (New England 
Biolabs, E2611) 
10 μl 
Deionized H2O 10 – X μl  
Total Volume  20 μl  
 
The samples were incubated at 50 degree Celsius in a thermocycler (MJ Research 
PTC-200 Thermal Cycler) for 15 minutes and stored on ice for the following heat-shock 
transformation.  
2.1.2 Polymerase Chain reaction (PCR) 
To perform a colony PCR, PCR tubes containing 50 μl of mQH2O were inoculated with 
colonies from the corresponding bacterial plate. Afterwards, the colonies were lysed at 
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100 degree Celsius for 10 minutes in a thermocycler (MJ Research PTC-200 Thermal 
Cycler) before being centrifuged for 25 seconds at 14000 g (Minispin Plus G, 
Eppendorf). For the PCR reaction, a Master mix containing mQH2O, buffer (Thermo 
Fisher Scientific, F530S), dNTP (BioNordika, BN-1006-08), forward and reverse primer 
(Sigma-Aldrich) and the Phusion DNA Polymerase (Thermo Fisher Scientific, F530S) 
was prepared. For a colony PCR the lysed colonies were used as the DNA template, 
while otherwise a plasmid was used as the DNA template. The composition of the PCR 
reaction is shown in Table 2. The PCR reaction was carried out in a thermocycler (MJ 
Research PTC-200 Thermal Cycler), for which the annealing temperature and the 
elongation time of the program were adapted accordingly. The steps of the PCR 
program are displayed in Table 3.  
Table 2. Composition of the Polymerase Chain Reaction (1x reaction). 
Reagent Volume of Components [µL] per reaction 
ddH2O x  
dNTP Mix (10 mM each), 
(BioNordika, BN-1006-08) 
1 
5x Phusion HF buffer 









2 U/µL Phusion™ High-
Fidelity DNA Polymerase 
(Thermo Fisher Scientific, 
F530S) 
0.25 




Table 3. PCR Program (30 circles of Denaturation, Annealing & Elongation). 
PCR Step  Temperature [°C] Time [s] 
Initialization 10 60 
Initial Denaturation 98 60 
Denaturation 98 30 
Annealing Template-dependent  30  
Elongation 72 30 sec/kb 
Final Elongation 72 600 
Final Hold 10 Unlimited time  
 
2.1.3 Agarose gel electrophoresis 
The Agarose gel was done by preparing 0.01 g/ml Agarose powder (Bioline, BIO-
41025) in 1x Tris acetate EDTA (TAE) solution in a microwaveable bottle. The 1x TAE 
solution was prepared by diluting a 50x TAE stock solution (Mixture of 242 g of Tris 
base, 57.1 mL of acetic acid, 100 mL of 0.5 M EDTA, pH 8.0) with ddH2O. The mixture 
was microwaved for 1 minute until the agarose was entirely dissolved. The agarose 
solution was cooled down to about 50 degree Celsius and SYBR® Safe DNA gel stain 
(Invitrogen, S33102) was added in a 1:10,000 ratio and mixed before the agarose gel 
was poured into the prepared Sub-Cell GT Horizontal Electrophoresis Cell (Bio-Rad, 
1704402). After the gel was solidified, the electrophoresis cell was filled with 1x TAE 
solution until the gel was covered. In the next step, the DNA samples were mixed with 
6x DNA Loading Dye (Thermo Scientific™, SM1334) and loaded into the wells of the 
gel. The molecular weight ladder (GeneRuler 1 kb Plus DNA Ladder, Thermo 
Scientific™, SM1334) was added to one well before the gel was run at about 100 V. 
The resulting gel bands were imaged by using the gel documentation system 




2.1.4 Gel extraction 
The extraction of DNA from an agarose gel was performed according to the protocol 
of the NucleoSpin® Gel and PCR Clean-up (Macherey-Nagel, 740609.50S).  
2.1.5 Ligation 
The ligation was carried out according to the manufacturer´s instruction of the 
NEBuilder HiFi DNA Assembly Reaction Protocol (New England Biolabs 2021, 
NEBuilder HiFi DNA Assembly Reaction Protocol). The reaction was set up on ice and 
the reaction components are shown in Table 4.  
Table 4. Composition of the DNA Assembly reaction (New England Biolabs 2021, NEBuilder HiFi DNA 
Assembly Reaction Protocol). 
Reagent 2 – 3 Fragment Assembly  
Recommended DNA Molar Ratio  vector:insert = 1:2  
Total Amount of Fragments  0.03 – 0.2 pmols*X μl  
NEBuilder HiFi DNA Assembly 
Master Mix (New England 
Biolabs, E2621S) 
10 μl 
Deionized H2O 10 – X μl  
Total Volume  20 μl  
 
The samples were incubated in a thermocycler (MJ Research PTC-200 Thermal 
Cycler) at 50 degree Celsius for 15 minutes and subsequently stored on ice for the 
following heat-shock transformation.  
2.1.6 Preparation of bacterial plates   
The solid LB-agar (Pronadisa, E00400) was slowly dissolved in the microwave before 
being transferred to a water bath (Julabo® water baths, Millipore Sigma, Z615471) with 
a set temperature of 50 degree Celsius. Once the temperature of the bottle dropped to 
50 degree Celsius, 75 µg/mL of the antibiotic Carbenicillin (Gibco™, 10177012) was 
added and the LB-agar was poured into 10 cm cell culture dishes. After drying, the 
plates were stored at 4 degree Celsius for further use.    
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2.1.7 Heat-shock transformation 
The competent DH5-α Escherichia coli cells (Thermo Fisher Scientific) were melted on 
ice for 30 minutes before 50 μl of the bacteria were mixed with the plasmid DNA of 
interest. After an incubation period of 30 minutes on ice, the mixture was given a heat-
shock at 42 degree Celsius for 45 seconds by using a heat block (Thermomixer 
comfort, Eppendorf). Then the mix was incubated for 5 minutes on ice and 250 μl of 
Lysogeny broth (LB) medium (HUS-Lab, T00053) were added followed by an 
incubation of 1 hour at 37 degree Celsius while shaking at 200 rpm (C25 Incubator 
Shaker, New Brunswick Scientific). In the last step the cells were plated on LB-Agar 
plates containing 75 µg/mL antibiotic Carbenicillin (Gibco™, 10177012) and the plate 
was incubated at 37 degree Celsius overnight.  
2.1.8 Bacterial overnight culture 
For the overnight culture, 15 ml of Terrific Broth medium (Thermo Fisher Scientific, 
A1374301) and 75 μg/ml of the antibiotic Carbenicillin (Gibco™, 10177012) were 
added to a 50 ml falcon tube. Under sterile conditions, the prepared falcon tube was 
inoculated with a bacterial colony or a bacterial culture stored as a glycerol stock before 
incubation at 37 degree Celsius while shaking at 200 rpm (C25 Incubator Shaker, New 
Brunswick Scientific).  
2.1.9 Plasmid extraction 
For the isolation of plasmid DNA, an overnight culture was prepared the night before. 
The next day, the overnight culture was centrifuged at 11,000 g for 1 minute (Sorvall 
LYNX 4000 Superspeed Centrifuge, Thermo ScientificTM), after which the cell pellet 
was used for the plasmid extraction. This method was performed according to the 
instructions of the NucleoSpin Plasmid Transfection-grade Kit (Macherey-Nagel, 
740490.50) and the centrifugation steps were performed by using the Biofuge Pico 
centrifuge (Heraeus). Subsequently, the plasmid concentration was measured with the 
BioSpec-nano Microvolume Spectrophotometer (Shimadzu).  
2.1.10 Glycerol stock preparation for long-term storage  
The overnight bacterial culture was mixed with 20% sterile glycerol in a cryotube 
(Thermo Scientific™, 377267) and stored on ice for 10 minutes before transfer to –80 
degree Celsius for long-term storage.  
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2.2 Cell culture methods 
2.2.1 Passaging and plating of the BT cells 
The medium for the patient-derived human glioblastoma cell lines BT12 and BT13 (Le 
Joncour et al., 2019) was prepared by adding 7.5 ml of 1M HEPES buffer (Lonza™ 
BioWhittaker™, BE17-737E), 10 ml B27 (Gibco™, 17504001), 5 ml of 200mM L-
glutamine (Gibco™, 25030-024), and 5 ml of penicillin-streptomycin (Lonza™ 
BioWhittaker™, DE17-602E) to 500 ml of DMEM/F12 medium (Gibco™, 11320033). 
The cell plate was taken from 37 degree Celsius and all liquid containing the cells that 
grow as non-adherent spheroids was collected and transferred to a falcon tube. The 
falcon tube was centrifuged at 1200 rpm for 3 minutes at room temperature (Universal 
32 R Centrifuge, Hettich) and the supernatant was carefully removed. Then 1 ml of the 
cell detachment solution Accutase (Sigma-Aldrich, A6964) was added to dissociate the 
cells from each other before the falcon tube was incubated at 37 degree Celsius for 3 
minutes. Afterwards, 5 ml of medium was added, and the cells were resuspended 
before the falcon tube was centrifuged at 1200 rpm for 3 minutes at room temperature. 
The supernatant was removed, and 10 ml of fresh medium containing the growth 
factors EGF (Peprotech, AF-100-15) and FGF (Peprotech, AF-100-18B), was added 
to the falcon tube and resuspended. For plating of cells in suspension, a small amount 
of the cell-medium solution was transferred to a new Eppendorf tube and mixed with 
Trypan Blue Solution, 0.4% (Gibco™, 15250061) in a 1:1 ratio. Then the cells were 
counted by using a light microscope (Motic, AE31E), the BT cell solution was added to 
the 24-well plate and the plate was incubated at 37 degree Celsius. 
For plating of coated BT cells, the Matrigel® Matrix Basement Membrane (Corning®, 
356230) was taken from –20 degree Celsius and put on ice at 4 degree Celsius for 
approximately 3 hours. Then, DMEM/F12 medium (Gibco™, 11320033) was 
transferred to an Eppendorf tube and Matrigel was added in a 1:50 ratio and 
resuspended. The solution was transferred to a 24-well plate and the plate was 
incubated at 37 degree Celsius for one hour. Following the incubation period, the 
Matrigel-medium solution was removed from the 24-well plate. The BT cells were 
passaged, counted by using a light microscope and the BT cell solution was added to 
the 24-well plate, which was then incubated at 37 degree Celsius. 
For maintenance, the cells were plated 1:2 on a new plate and 2 μl of the recombinant 
human epidermal growth factor (EGF, Peprotech, AF-100-15) and 1 μl of the 
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recombinant human fibroblast growth factor (FGF-basic, Peprotech, AF-100-18B) were 
added to the plate. The plate was then incubated at 37 degree Celsius. Every second 
day growth factors were added, and the cells were passaged once they reached a 
confluency level of 80 to 90 percent.  
2.2.2 Passaging of HEK293FT cells 
The medium for the human embryonic kidney cell line HEK293FT (Thermo Fisher 
Scientific) was prepared by adding 50 ml fetal bovine serum (Gibco™, 10500-064), 5 
ml of 200mM L-glutamine (Gibco™, 25030-024) and 5 ml of penicillin-streptomycin 
(Lonza™ BioWhittaker™, DE17-602E) to 500 ml of DMEM (4.5 g/L D-glucose) medium 
(Gibco™, 11960044). The 10 cm cell dish was taken from 37 degree Celsius and the 
supernatant was carefully aspirated before the plate was washed twice with 5 ml of 
phosphate-buffered saline (PBS) (Medicago, 09-9400-100). Then 2 ml of the cell 
dissociation solution Trypsin EDTA (Lonza™ BioWhittaker™, BE17-161E) was added, 
and the cell dish was incubated at 37 degree Celsius for 3 to 5 minutes. In the next 
step all liquid was collected from the cell plate and transferred to a 15 ml falcon tube 
before centrifugation at 1200 rpm for 3 minutes at room temperature (Universal 32 R 
Centrifuge, Hettich). The supernatant was aspirated, and the cell pellet resuspended 
in 10 ml of DMEM medium. The cells were then plated 1:10 in a new cell culture plate 
and the plate was incubated at 37 degree Celsius. The cells were passaged once a 
confluency level of approximately 80% was reached. 
2.2.3 Passaging of OP9 cells  
The medium for the OP9 cells was prepared by adding 50 ml of fetal bovine serum 
(Gibco™, 10500-064), 5 ml of 200mM L-glutamine (Gibco™, 25030-024) and 5 ml of 
penicillin-streptomycin (Lonza™ BioWhittaker™, DE17-602E) to 500 ml of Minimum 
Essential (MEM) Alpha Medium (Gibco™, 22561-021). The 10 cm cell dish was taken 
from 37 degree Celsius and the supernatant was carefully aspirated before the plate 
was washed twice with 5 ml of PBS (Medicago, 09-9400-100). The PBS was removed, 
and 2 ml of the cell dissociation solution Trypsin EDTA (Lonza™ BioWhittaker™, 
BE17-161E) was added per 10 cm dish and then incubated for 3 to 5 minutes at 37 
degree Celsius. After the incubation period, 8 ml of the medium was added to the cells 
and the cell solution was transferred to a falcon tube before centrifugation at 1200 rpm 
for 3 minutes (Universal 32 R Centrifuge, Hettich). The supernatant was removed, and 
10 ml of fresh medium was added. The cells were then plated 1:2 in a new cell culture 
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plate and the plate was incubated at 37 degree Celsius. The cells were passaged once 
a confluency level of 80% was reached. 
2.2.4 Thawing of cells  
The cryotubes (Thermo Scientific™, 377267) containing cells were taken from –80 
degree Celsius and put on ice. After the cells were thawed, 1 ml of appropriate medium 
was added to the cryotubes and resuspended. In the next step, a new falcon tube with 
9 ml of medium was prepared, before the cell solution was transferred from the 
cryotube to the falcon tube and resuspended in the medium. Subsequently the falcon 
tube was centrifuged at 1200 rpm for 3 minutes at room temperature (Universal 32 R 
Centrifuge, Hettich) before the supernatant was removed. As a last step, 10 ml of new 
medium were added to the falcon tube and the solution was transferred to a new plate. 
The plate containing the cells was then incubated at 37 degree Celsius.  
2.2.5 Freezing of cells  
The cell plate containing cells in suspension was taken from 37 degree Celsius and all 
cells were collected in a falcon tube and centrifuged at 1200 rpm for 3 minutes 
(Universal 32 R Centrifuge, Hettich) at room temperature before the supernatant was 
removed. Then an Eppendorf tube containing 90% of medium and 10% of the 
cryopreservation agent Dimethyl sulfoxide (DMSO, Sigma-Aldrich, D8418) was 
prepared and 1 ml of this solution was added to the falcon tube containing the cells 
and subsequently resuspended. Next all the solution in the falcon tube was transferred 
to a cryotube (Thermo Scientific™, 377267), which was labelled and kept on ice for 10 
minutes before being transferred to the –80 degree Celsius for long-term storage. To 
freeze adherent cells, the cell dishes were treated with Trypsin EDTA (Lonza™ 
BioWhittaker™, BE17-161E) first to dissociate the cells from the plate and then 
centrifuged at 1200 rpm for 3 minutes (Universal 32 R Centrifuge, Hettich) before 
freezing the cells according to the instructions for suspension cells.   
2.2.6 MTT assay  
The volume of cell-medium solution in the plate wells was estimated and the required 
amount of the MTT reagent Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich, 
M5655) was added to each well (10% of the volume/well). After incubating the plate 
for 2 hours at 37 degree Celsius, MTT lysis buffer (50 ml of 20% SDS, 83 μl of 37% 
HCl and 100 μl of ddH2O) was added to the wells. The plate was then incubated 
overnight at 37 degree Celsius overnight. The next day, the plate was measured at an 
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optical density of 540 nm by using a Microplate reader (FLUOstar® Omega, BMG 
Labtech). The data from the Microplate reader was analyzed using the Omega Data 
Analysis software (BMG Labtech).  
2.3 Exosome methods  
2.3.1 Sample collection for exosome isolation 
The HEK293FT or OP9 cells were cultured on 15x15 cm cell culture dishes. Two days 
before the sample collection, the medium was changed to medium containing exosome 
depleted fetal bovine serum (Gibco™, A2720801). After 48 hours of incubation time at 
37 degree Celsius, the supernatant from the cell culture dishes was transferred to a 50 
ml falcon tube. The falcon tubes containing the supernatants were centrifuged at 300 
g for 5 minutes (Universal 32 R Centrifuge, Hettich) at room temperature before 
transferring the supernatant to a new 50 ml falcon tube and centrifuging at 1250 g for 
10 minutes (Universal 32 R Centrifuge, Hettich) at room temperature. In the last step, 
the supernatant was transferred to another 50 ml falcon tube and then filtered with a 
sterile Minisart Syringe filter (Pore Size 0.22 µm, Sartorius, 16532) into a 50 ml falcon 
tube before storage at -20 degree Celsius until further use.  
2.3.2 Exosome isolation 
The exosomes were isolated from HEK293FT or OP9 derived supernatant that had 
been prepared and stored at -20 degree Celsius as described in the previous chapter. 
The supernatants were then thawed in a warm water bath and concentrated by using 
the Millipore Amicon ultra-15 100 K (Merck, UFC910024) filter tubes. The upper 
chamber of the filter tubes was filled with the supernatant and then the tubes were 
centrifuged at 4000g for 10 minutes (Sorvall LYNX 4000 Superspeed Centrifuge, 
Thermo ScientificTM) at room temperature. In the next step, the flow-through was 
discarded before the upper chamber was refilled with the supernatant and another 
centrifuge step took place. This process was repeated until all supernatant had been 
concentrated to about 500 μl. While the centrifuge process took place, the qEVoriginal 
Size Exclusion Column (Izon Science, SP1) was taken from 4 degree Celsius and 
equilibrated at room temperature before washes with 20 ml of PBS (Medicago, 09-
9400-100). Here the time was measured for collecting 5 ml in a measuring cylinder, to 
ensure the quality of the qEVoriginal Size Exclusion Column. Once the washes were 
done, the 500 μl of supernatant were added slowly and evenly on top of the Size 
Exclusion column (SEC) membrane. After all the supernatant had passed through the 
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filter, PBS was added again, and the fractioning took place. The first 3 ml were 
discarded, while the last 1.5 ml, which contained the exosomes were collected in an 
Eppendorf tube and stored at –80 degree Celsius. Then the Size Exclusion column 
was washed with 40 ml of PBS and the time was measured for collecting 5 ml in a 
measuring cylinder. This was followed by 7 washes with a 20% EtOH-PBS solution. 
Then, 2 ml of the 20% EtOH-PBS solution was left in the column, the bottom and top 
were sealed with parafilm (Sigma-Aldrich, P7543) and the SEC column was stored at 
4 degree Celsius.  
2.3.3 Transfection of plasmids with/without exosomes   
Exosome aliquots, each containing about 50 μl of isolated exosomes, were taken from 
–80 degree Celsius and thawed at 37 degree Celsius. Approximately five to six hours 
later, the transfection reagent Fugene HD (Promega, E2311) was equilibrated at room 
temperature for 10 minutes, while the plasmids were taken from –20 degree Celsius 
and thawed at room temperature. For each transfection, tube A with 150 μl PBS 
(Medicago, 09-9400-100) and tube B with 75 μl of PBS were prepared. Then 3 μg of 
plasmid was added to tube A, while 12 μl of Fugene HD solution was added to tube B. 
Subsequently the tubes A and B were incubated for 5 minutes at room temperature 
before mixing them. After another incubation period of 15 minutes at room temperature, 
the exosomes were added to the plasmid/Fugene HD solution. The transfected 
exosomes were then incubated at 37 degree Celsius for about 18 hours. 
To test the functionality of constructed plasmids, tube A with 150 µl PBS and 3 µg of 
the new plasmid construct was prepared, while tube B contained 75 µl PBS and 12 µl 
of the transfection reagent Fugene HD. Before mixing, both tube A and B were 
incubated at room temperature for 5 minutes. Then, another incubation period of 15 
minutes at room temperature took place before the solution was inoculated directly into 
the target cells. The cells were incubated at 37 degree Celsius for up to 4 days before 
imaging. During imaging, the cells were checked for apoptotic signs in case of targeting 
plasmids or fluorescent signal if non-targeting plasmids containing fluorescent proteins 
were used.  
2.3.4 Inoculation of target cells with transfected exosomes  
After incubation of the transfected exosomes at 37 degree Celsius, they were 
transferred to 10 K Amicon® Ultra 0.5 mL Centrifugal Filters (Merck, UFC501024). The 
filter tubes were topped up to 450 μl with PBS (Medicago, 09-9400-100) before 
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centrifugation at 6100 g for 15 minutes (Minispin Plus G, Eppendorf) at room 
temperature. The flow-through was discarded and PBS was added to the filter tubes 
once more before the tubes were centrifuged at 6100 g for 20 minutes (Minispin Plus 
G, Eppendorf) at room temperature. Subsequently, this step was repeated at 6100 g 
for 25 minutes (Minispin Plus G, Eppendorf) at room temperature. Next, the filter tubes 
were inverted into a new 10 K Amicon® Ultra 0.5 mL Centrifugal Filter tubes and 
centrifuged at 1000 g for 2 minutes (Minispin Plus G, Eppendorf) at room temperature 
before the filters were discarded and the transfected exosomes, remaining in the tubes, 
inoculated into the target cells.  
In some experiments we used a variation of the protocol with addition of DNAse I 
treatment. After incubation of transfected exosomes at 37 degree Celsius, they were 
transferred to Amicon® Ultra 0.5 mL Centrifugal Filters with the filter pore size varying 
from 50K (Merck, UFC505024) to 100K (Merck, UFC510024). Then the filter tubes 
were topped up to 450 μl with PBS (Medicago, 09-9400-100) before centrifugation at 
4000 g for 10 minutes (Minispin Plus G, Eppendorf) at room temperature. 
Subsequently the flow-through was discarded and DNAse I (New England Biolabs, 
M0303S) was mixed with PBS in a ratio of 1:80 and added to the filter tubes. The filter 
tubes were filled with 400 μl of this mixture and incubated for 15 minutes at room 
temperature. After the incubation, the filter tubes were centrifuged at 4000 g for another 
10 minutes (Minispin Plus G, Eppendorf) before the flow through was discarded and 
the tubes were topped up to 450 μl with PBS and centrifuged again at 4000 g for 10 
minutes (Minispin Plus G, Eppendorf) at room temperature. The filter was then inverted 
in a new Amicon® Ultra 0.5 mL Centrifugal Filter tube and centrifuged at 1000 g for 2 
minutes (Minispin Plus G, Eppendorf) at room temperature. As the last step, the filter 
was discarded, and the transfected exosomes were inoculated into the target cells.  
2.4 Virus-related methods 
2.4.1 Production of lentiviruses 
All experiments including lentiviruses were performed in the Biosafety Level 2 (BSL-2) 
laboratories due to the moderate risk associated with the viruses upon swallowing or 
contact with the skin.  
One day prior the transfection, the HEK293FT cells were passaged and cultured for 
24 hours to a confluence of approximately 80%. On the next day, the DMEM (4.5 g/L 
D-glucose) medium (Gibco™, 11960044) and Opti-MEM (Gibco™, 31985-047) were 
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warmed up at 37 degree Celsius and the transfection reagent Fugene HD (Promega, 
E2311) was kept at room temperature for 10 minutes before the use. The cell culture 
medium was carefully changed to 5 ml of fresh and warm DMEM medium and the 
transfection mixes were prepared in tubes A and B. In tube A, the target plasmid, the 
packaging plasmid CMV delta 8.3 (Addgene) and the envelope plasmid CMV-G 
(Addgene) were mixed with Opti-MEM, while tube B contained the transfection reagent 
Fugene HD in Opti-MEM. The tubes were flicked to mix and incubated at room 
temperature for 5 minutes before combination to one tube AB. Then this tube was 
flicked to mix again and incubated for another 20 minutes at room temperature. The 
transfection mix in tube AB was then added dropwise to the HEK293FT cells before 
the cells were transferred to the 37 degree Celsius incubator in the BSL-2 room. After 
an incubation period of 48 hours, the medium containing the lentivirus was collected 
and filtered through a sterile Minisart 0.45 µm syringe filter (Sartorius, 16537) into a 50 
ml falcon tube and the cells were supplemented with 5 ml of fresh and warm DMEM 
medium. The falcon tube was sealed with Parafilm (Sigma-Aldrich, P7543) and stored 
at 4 degree Celsius overnight. After 24 hours of incubation time, this process was 
repeated and the virus containing medium was collected and sterile filtered, before 
combination with the medium collected a day prior. The harvested viral particles were 
aliquoted in 1 ml aliquots in cryotubes (Thermo Scientific™, 377267) and stored at -80 
degree Celsius. 
2.4.2 Transduction of OP9 cells with virus supernatant  
The OP9 cells were transduced with the lentivirus to enhance the targeting of the 
glioblastoma cells. For this, the murine, mesenchymal progenitor OP9 cell line was 
cultured and passaged. After a centrifugation step at 1200 rpm for 3 minutes (Universal 
32 R Centrifuge, Hettich), 10 ml of MEM Alpha Medium (Gibco™, 22561-021) was 
added and the cells were plated into 3 wells of a 6-well plate and 6 wells of a 24-well 
plate. The plates were incubated at 37 degree Celsius for 24 hours. Then, 0.5 μl, 1 μl, 
2 μl, 3 μl or 4 μl of the antibiotic Puromycin (Sigma-Aldrich, P8833) was added to the 
24-well plate but leaving one well untreated as a negative control. The plate was then 
incubated in the BSL-2 room at 37 degree Celsius and carefully monitored. After 2 to 
3 days, the appropriate Puromycin antibiotic (Sigma-Aldrich, P8833) concentration was 
decided, needed for an antibiotic growth curve selection. The next day the virus 
transduction was performed by adding 2 ml of OP9 cells and 2 ml of virus containing 
medium to a 6-well plate before adding the cationic polymer Hexadimethrine bromide 
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(Polybrene, Sigma-Aldrich, 107689) in a 1:1,000 concentration and incubating at 37 
degree Celsius in the BSL-2 room for 2 days. Polybrene was added during this step, 
since it has been shown to enhance the transduction efficiency of cells with lentivirus 
(H. E. Davis et al., 2002). After 24 hours the medium was changed and after 48 hours 
the cells were divided to two 10 cm cell culture dishes. One of the 10 cm plates was 
supplemented with 30 μl of the antibiotic Puromycin, while the second plate was 
supplemented with 40 μl of Puromycin. Since the lentiviral vector resulted in resistance 
to the antibiotic Puromycin, this antibiotic was added to select the transduced cells 
while eliminating the non-transduced cells (Addgene 2019). The virus transduced OP9 
cells were passaged once they reached a confluent state and were continuously 
cultured on 15x15 cm plates, at which point the cells could be used for the isolation of 
exosomes (“2.3.1 Sample collection for exosome isolation”).  
2.5 Imaging 
2.5.1 Thermo EVOS FL 
The target cells with the transfected exosomes were imaged using the Widefield 
Microscope Thermo EVOS FL provided by the Biomedicum Imaging Unit 
(https://www2.helsinki.fi/en/infrastructures/bioimaging/biomedicum-imaging-unit). The 
cells containing exosomes transfected with targeting plasmids were monitored for 
signs of apoptosis, such as cell shrinkage and blebbing, while the cells inoculated with 
exosomes transfected with control non-targeting plasmids but including mCherry (red) 
or enhanced green fluorescent protein (eGFP) fluorophores were checked for a 
corresponding signal.  
2.5.2 Bioluminescence Imaging 
To test for bioluminescence in the OP9 cells in order to confirm the presence of the 
NanoLuc® (NLuc) luciferase enzyme in the cells and thereby a successful virus 
transduction, a plate containing control conditions with the wildtype OP9 cells and test 
conditions, which included virus transduced OP9 cells, was imaged. The Nano-Glo® 
Luciferase Assay System (Promega, N1110) was added to the control and test 
conditions and subsequently this plate was imagined using the Spectral Instruments 
Imaging Lago small animal imaging system, which was provided by the Biomedicum 
Imaging Unit – IVI. A successful virus transduction of the OP9 cells was confirmed in 
case of bioluminescent signal due to the expression of the NLuc luciferase enzyme in 





3.1 Targeting plasmids for common genetic alterations in glioblastoma cells lack 
transfection efficiency  
 
This research project focuses on plasmids targeting genetic alterations in glioblastoma 
cells. The selected plasmids encode oncoproteins or tumor suppressor proteins, which 
have been shown to decrease proliferation in cancer cells when silenced or 
upregulated. The first step in setting up the exosome-based gene therapy comprised 
of testing the most efficient plasmids with the potential to decrease proliferation of 
glioblastoma cells.  
The targeting plasmids and their corresponding controls (non-targeting plasmids) are 
displayed in Table 5. Targeting plasmids were constructed to silence the expression of 
the oncogene EGFRvIII and to overexpress the tumor suppressor genes PTEN and 
TP53.  
Table 5. Targeting plasmids and the corresponding control non-targeting plasmids.  
Targeting plasmids Non-targeting plasmids  
pNL1.1_CMV_mCherry_shEGFRvIII  pNL1.1_CMV_mCherry_shNEGATIVE   
pNL1.1_pmir21_PTEN  pNL1.1_pmir21_gfp_shNEGATIVE  
pNL1.1_pmir21_TP53  pNL1.1_CMV_mCherry_shNEGATIVE 
 
These plasmids had been constructed prior to this research project and therefore I 
started by transfecting them into exosomes and inoculating them into the glioblastoma 
cells to test their efficacy. The addition of exosomes was repeated two more times to 
increase the efficiency of the targeting. The cells were imaged 48 hours after the 3rd 
inoculation with transfected exosomes using the Widefield Microscope Thermo EVOS 
FL. The BT12 glioblastoma cells, treated with a combination of the targeting plasmids, 
showed signs of cell death, while the cancer cells treated with the non-targeting 
plasmids proved the successful uptake of the transfected exosomes by the target cells 
as judged by the fluorescent signals for mCherry and eGFP. The majority of the control 




Three inoculations of exosomes were necessary to detect visible fluorescence signal 
(Figure 1). The size of these plasmids was approximately 5700 bp and the large size 
probably decreased the transfection efficiency and the uptake of the plasmids into the 
exosomes. Therefore, we decided to test smaller plasmids, which utilize apoptosis-
inducing proteins to increase the efficiency and decrease the number of necessary 
inoculations.  
3.2 Design of targeting plasmids utilizing apoptosis-inducing proteins to increase 
transfection efficiency in glioblastoma cells 
   
The following plasmids were designed and subsequently tested.  
The targeting plasmid encoding Granzyme B enzyme (GzmB) was constructed by 
purchasing the hpmir21-GzmB vectors from the VectorBuilder. Subsequently, GzmB 
was subcloned (2.1.5 Ligation) into the Miniplasmid pUCmu to reduce the size of the 
plasmid construct, which positively influences the efficiency of the exosome 
transfection (Hardee et al., 2017). The successful insertion of GzmB into pUCmu was 
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verified using colony PCR. The gel electrophoresis picture is displayed in Appendix A. 
Due to the anticipated low transfection efficiency of plasmid DNA into the exosomes, 
the gene of interest needed to be very efficiently expressed in the target cells. To 
achieve this, we added a nuclear localization sequence (NLS) and a DNA translocation 
sequence (DTS) to the plasmid. The DTS sequence 
(GGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCAT
CTCAATTAGTCAGCAACCA) resulted in a plasmid translocation from the cytosol to 
the nucleus, thereby enhancing gene transcription, while the NLS sequence 
(CCAAAAAAGAAGAGAAAGGTA) enhanced the translocation of the GzmB protein to 
the nucleus, where the damage took place. The corresponding control for the GzmB 
targeting plasmid was created by substituting the GzmB sequence with the fluorescent 
protein eGFP by using the assembly cloning HiFi (2.1.5 Ligation). The primer 
sequences used for the cloning and verification of the targeting and non-targeting 
plasmids are displayed in Appendix B. The maps displaying the targeting plasmid 






The targeting plasmid encoding the sequence for Diphtheria toxin fragment A (DTA) 
was constructed by purchasing the hpIL13RA2-DTA vectors from VectorBuilder and 
subsequently subcloning the DTA into the Miniplasmid pUCmu by using the DNA 
assembly HiFi from NEB (2.1.5 Ligation) to decrease the size of the plasmid construct. 
The successful cloning was verified by colony PCR. The gel electrophoresis picture is 
displayed in Appendix A. The DTA plasmid was further modified by adding the DTS 
sequence resulting in the plasmid translocation from the cytosol to the nucleus to 
improve the gene transcription process. The NLS sequence was not added to the 
plasmid since the DTA effect occurs in the cytoplasm by inhibition of the protein 
synthesis. The DTA sequence of the plasmid was then substituted with the sequence 
encoding the fluorescent protein mCherry (2.1.5 Ligation) to create the corresponding 
control for the DTA plasmid. The primer sequences used for the cloning and verification 
of the targeting and non-targeting plasmids are shown in Appendix B. The maps 
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displaying the targeting plasmid with DTA and the corresponding mCherry control are 






The final targeting plasmid constructs, and their corresponding controls are displayed 
in Table 6. 
Table 6. Targeting plasmids and corresponding control plasmids for Granzyme B and Diphtheria toxin 
fragment A. 
Targeting plasmid Control 
pUCmu-DTS-hpmir21-dGzmB + NLS 3x pUCmu-DTS-hpmir21-eGFP 
pUCmu-DTS-pIL13RA2s-DTA pUCmu-DTS-pIL13RA2s-mCherry 
 
3.3 Isolation of exosomes as carriers for gene therapy in glioblastoma cells 
3.3.1 Exosomes derived from the HEK293FT cell line used as main exosome source 
 
The HEK293FT laboratory stock was selected for the isolation of exosomes due to the 
fast growth and simple culture conditions. In addition, due to yet unknown reasons, 
HEK293FT cells target glioblastoma cells very efficiently. 
To confirm that the effect on the target cells is exclusively due to the plasmids that 
have been transfected into the exosomes and not due to external plasmid, we isolated 
HEK293FT-derived exosomes, transfected the exosomes with the non-targeting 
plasmid pNL1.1_CMV_mCherry_shNEGATIVE including the mCherry protein, and 
inoculated the transfected exosomes into a different set of HEK293FT cells. The 
control conditions did not contain exosomes, but only the plasmid and the transfection 
reagent Fugene HD. Both, the control and targeted cells were treated with the DNAse 
I enzyme to remove extra plasmids that had not been taken up by the exosomes during 
the transfection process. The cells were imaged 48, 96 and 144 hours after the 





The results confirmed that addition of the DNAse I enzyme eliminated any external 
plasmids not taken up by the exosomes. Thus, only the plasmids taken up by 
exosomes showed a positive fluorescent signal.  
3.3.2 Exosomes derived from the virus-transduced OP9 cell line used as alternative 
exosome source  
 
We used the murine mesenchymal progenitor OP9 cell line as an alternative source 
for the isolation of exosomes. For that purpose, OP9 cells were transduced with 
lentiviruses, encoding the tumor homing peptide iRGD and NanoLuc® luciferase 
enzyme. The successful lentiviral transduction was confirmed using the 
Bioluminescence imaging after addition of the Nano-Glo® Luciferase Assay System 
(Figure 7). As a result, the exosomes isolated from the virus transfected OP9 cells, 
carried the homing peptide iRGD on the surface, enabling a more efficient uptake of 




In addition to the use of the iRGD homing peptide, another goal was to track the 
exosomes in vivo via the expression of the NanoLuc® luciferase enzyme by virus-
transduced cells. The expression of luciferase enzyme by the exosomes was verified 
by treatment of the cells with Furimazine, a substrate to the NanoLuc. Treatment 
resulted in high-intensity luminescence only when the lentivirus transduced cells were 
treated with Nano-Glo® Luciferase Assay System (Figure 8).  





3.4 Study of targeting and non-targeting plasmids in glioblastoma cells for exosome-
based gene therapy 
3.4.1 Testing of plasmid construct efficiency for exosome-based gene therapy in 
glioblastoma cells 
 
The efficiency in inducing apoptosis of the targeting plasmids encoding the Granzyme 
B and Diphtheria toxin fragment A and their corresponding controls encoding eGFP 
and mCherry (Table 6) was tested by transfecting the BT12 cells with plasmids without 
exosomes. Cells were imaged using the Widefield Microscope Thermo EVOS FL 72 
hours after transfection. Our results showed a fluorescence signal in cells transfected 
with the control plasmids and signs of cell death of cells transfected with the targeting 





To further test the efficacy of the plasmid constructs, an MTT assay was 
conducted to measure the effect of the different plasmids on cell viability. 
MTT assay confirmed the decrease in cell viability for the targeting plasmids 
pUCmu-DTS-pIL13RA2s-DTA and pUCmu-DTS-hpmir21-dGzmB + NLS 3x 
(Figure 10). Cells transfected with the non-targeting plasmid pUCmu-DTS-
hpmir21-eGFP showed an increased cell viability compared to the control 
non-transfected cells, while the non-targeting plasmid pUCmu-DTS-
pIL13RA2s-mCherry resulted in a minor decrease of the cell viability (Figure 
10). 






3.4.2 Enhancing of targeting plasmid encoding Granzyme B shows improved 
transfection efficiency in glioblastoma cells 
 
The cell death induced by Granzyme B is one of the mechanisms used by the human 
body to kill tumor cells and therefore, this enzyme is a potential candidate for inducing 
apoptosis in glioblastoma cells. First, I transfected the isolated exosomes with the 
targeting plasmid hpmir21-dGzmB following inoculation of exosomes to BT12 
glioblastoma cells. Treated cells were imaged 72 hours after the 2nd inoculation with 
transfected exosomes using the Widefield Microscope Thermo EVOS FL. The 
Granzyme B expressing cells showed signs of apoptosis in comparison with the 




Therefore, we decided to further increase its targeting efficiency by addition of the DTS 
and NLS sequences in the plasmid (DTS-hpmir21-dGzmB + NLS 3x).  
The BT12 glioblastoma cells were treated with the isolated enhanced Granzyme B 
plasmid transfected exosomes and imaged 96 hours after the 1st exosome inoculation 
using the Widefield Microscope Thermo EVOS FL. MTT assay to assess the cell 
viability was performed on day 5 after the 1st exosome inoculation.  
Both, the imaging (Figure 12) and the MTT assay (Figure 13) verified the cell death 
and decreased cell number of the cells treated with granzyme B transfected exosomes 









Granzyme B reduced the cell viability by 81% compared to the control non-treated cells 
(Figure 13) thereby confirming the efficacy of this approach. Since the plasmid size 
influences the transfection efficiency, we decided to study if decreasing the size of the 
Granzyme B encoding plasmid would further increase the efficiency of the targeting.  
3.4.3 Targeting plasmid pUCmu-DTS-hpmir21-dGzmB + NLS 3x results in highest 
transfection efficiency 
 
The enhanced Granzyme B encoding plasmid containing the DTS and NLS sequences 
was subcloned into the miniplasmid pUCmu, which decreased the size of the overall 
construct by 600 bp and thereby potentially influenced the transfection efficiency. I then 
transfected the pUCmu plasmid construct into the HEK293-derived exosomes and 
treated the BT12 glioblastoma cells. 72 hours after the 1st exosome inoculation the 
cells were imaged using the Widefield Microscope Thermo EVOS FL and an MTT 
assay was performed the following day. The images showed apoptosis and a 
decreased cell number of the cells treated with the granzyme B exosomes in 
comparison to the control cells treated with the non-targeting plasmid (Figure 14).  
 
Viability of the cells treated with the granzyme B exosomes was reduced by 93,1% 
compared to the non-treated control cells (Figure 15). Reduction in cell viability was 
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about 12% more with the smaller plasmid confirming the effect of the size reduction in 
the transfection efficiency. However, also viability of the control cells treated with the 
non-targeting plasmid pNL1.1_CMV_mCherry_shNEGATIVE reduced by 32,8% 
compared to the non-treated control cells (Figure 15). Overall, the results with the 
plasmid construct pUCmu-DTS-hpmir21-dGzmB + NLS 3x were promising.  
 
To make sure that only the plasmids, that have been taken up by the exosomes 
affected the target cells, I added the DNAse I enzyme during the centrifugation of the 
filter tubes with the transfected exosomes, followed by the inoculation into the BT12 
glioblastoma cells. This enzyme cleaves DNA and therefore degraded all plasmids 
outside the exosomes, ensuring that the effect on target cells was a result of the 
exosome-based gene therapy. Cell viability was determined by using the MTT assay 
96 hours after the inoculation of the transfected exosomes. 
Cell viability decreased by 15,9% in the cells treated with the targeting plasmid pUCmu-
DTS-hpmir21-dGzmB + NLS 3x compared to the control cells treated with the non-
targeting plasmid pNL1.1_CMV_mCherry_shNEGATIVE (Figure 16). However, the 
decrease in cell viability after the DNAse I addition was less compared to the cell 
viability without the addition of DNAse I (Figure 15), indicating that part of this detected 




3.4.4 Study of varying conditions to test potential effect of reaction components on 
glioblastoma cell viability 
 
To clarify the effect of the exosomes, the transfection reagent, and the plasmids not 
taken up by the exosomes on the target cell viability, different conditions were 
analyzed.  
In every set-up, five different conditions were tested with the first condition set as a 
control containing only cells, while the second condition contained cells incubated with 
the PBS buffer. For the third condition, a mock exosome transfection was carried out 
without addition of exosomes, to make sure that only the plasmids taken up by the 
exosomes led to an effect on target cells. The fourth condition comprised an exosome 
transfection, in which the plasmid was substituted with PBS, to test the effect of the 
transfection reagent Fugene HD. For the fifth condition an exosome transfection was 
conducted, and all components were added. For all five conditions, the DNAse I 
enzyme was added during the centrifugation steps preceding the inoculation into the 
BT12 glioblastoma cells to remove external plasmids outside of the exosomes.  
In addition, the parameters tested included varying pore sizes of the centrifugal filter 
tubes (50 kDa or 100 kDa) used during the centrifugation of the filter tubes with the 
transfected exosomes before inoculation into the BT12 glioblastoma cells, the source 
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of the exosomes (HEK293FT cells or virus transfected OP9 cells) and the BT12 cells 
grown either in suspension or as an adherent culture. 
The cells were imaged 96 hours after the 1st exosome inoculation using the Widefield 
Microscope Thermo EVOS FL and an MTT assay was performed the following day. 
Both cell imaging (Figure 17) as well as the MTT cell viability assay data (Figure 18) 
indicate that the pUCmu-DTS-hpmir21-dGzmB + NLS 3x plasmid transfected into 
HEK293-derived exosomes and isolated using the 50 kDa centrifugal filter tubes 
resulted in decreased cell viability of approximately 11% compared to control condition 
4 containing Fugene HD and exosomes, which showed the lowest cell viability out of 
the other conditions (Figure 18). For the condition 3 where no exosomes were present, 
an increase in cell viability was detected, indicating that the addition of DNAse I 
enzyme successfully removed extra plasmids, not taken up by the exosomes. Thus, 
no effect on the viability of target cells was detected (Figure 18). Overall, the highest 
decrease in cell viability (approximately 22%) resulted when cells were treated with the 





The same five conditions were applied to exosomes isolated from the virus transfected 
OP9 cells and isolated using the 100 kDa centrifugal filter tubes.  
The cells were imaged 96 hours after the 1st exosome inoculation using the Widefield 
Microscope Thermo EVOS FL and an MTT assay was performed the following day. 
Both cell imaging (Figure 19) as well as the MTT cell viability results (Figure 20) 
showed a decrease in cell viability in the conditions 3 to 5 which all contained Fugene 
HD (Figure 20). The highest decrease in cell viability (about 58%) was detected in the 
exosome therapy (condition 5) (Figure 20). Cell viability in this group was about 15% 
lower compared to the conditions 3 and 4 (Figure 20). This is in accordance with the 






Then, the same five conditions were applied to the exosomes isolated from HEK293FT 
cells and isolated by using 100 kDa centrifugal filter tubes. The cells were imaged 96 
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hours after the 1st exosome inoculation using the Widefield Microscope Thermo EVOS 
FL and an MTT assay was performed the following day. Cell imaging (Figure 21) 
showed less cells in conditions 3 and 4 compared to the non-treated control cells, 
which was confirmed by the MTT cell viability results (Figure 22). The MTT assay 
showed that the cell viability of conditions 3 and 4 was decreased by approximately 
13%, while the viability of cells treated with the exosome-based gene therapy showed 
the highest decrease (approximately 19%) of cell viability compared to conditions 3 
and 4 (Figure 22). The result of highest cell viability decrease in cells treated with the 
exosome-based gene therapy is in accordance with the results obtained for the 
exosomes isolated from the HEK293FT cells and isolated by using 50 kDa filters. The 
decrease in the viability of PBS treated cells differs from all previous experiments that 
have not shown any decrease in cell viability. Therefore, it represents an outlier and 





Taken together, the decrease in viability of the cells treated with exosome gene therapy 
has varied in between 11% to 19% compared to the control conditions, indicating that 
the effect on the target cells is not dependent on the source of the exosomes or the 
pore sizes of the centrifugal filter tubes. Furthermore, the effect of the exosome therapy 
on cell viability overrides that of the transfection reagent Fugene HD or the effect of 
the exosomes, indicating specific effect of the exosome-based gene therapy.  
Next, the BT12 cells were plated as adherent cells by using Matrigel. In addition to this 
change, a new condition was added, where the transfection reagent Fugene HD was 
replaced with PBS buffer to test if any passive diffusion of plasmids into the exosomes 
without the presence of a transfection reagent occurred. The cells were imaged 96 
hours after the 1st exosome inoculation using the Widefield Microscope Thermo EVOS 
FL and an MTT assay was performed the following day. Cell imaging (Figure 23) 
showed less cells in the exosome-based gene therapy treated cells. This was 
confirmed by the MTT cell viability assay (Figure 24). The highest decrease 
(approximately 14%) in viability occurred in cells treated with exosome gene therapy 





After studying the different conditions and set-ups, the viability of cells treated with 
exosome therapy containing the pUCmu-DTS-hpmir21-dGzmB + NLS 3x plasmid 
consistently showed the lowest number of live cells varying between 10 – 20% 
decrease compared to the other control conditions.   
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3.4.5 Targeting plasmid encoding Diphtheria toxin fragment A reduces cell viability in 
glioblastoma cells 
 
The Diphtheria toxin fragment A (DTA) is characterized by a high toxicity due to an 
inhibition of protein synthesis by inactivating the eukaryotic elongation factor 2 (EF2). 
EF2 is highly expressed in a variety of malignant tumor cells and its expression shows 
correlation with the cancer progression and recurrence, making it a potential candidate 
for an anti-cancer agent. To study the efficacy of DTA in exosome-based gene therapy 
plasmid DTS- pIL13RA2s-DTA was transfected into the HEK293FT-derived exosomes 
and inoculated to the BT12 glioblastoma cells. This experiment was repeated twice 
with two independent exosome inoculations. The cells were imaged 72 hours after the 
2nd inoculation of transfected exosomes using the Widefield Microscope Thermo EVOS 
FL and an MTT assay was performed the following day. Cell imaging (Figure 25) 
showed less cells and signs of apoptosis when cells were treated with the targeting 







An additional independent exosome inoculation was carried out, for which the cells 
were imaged 96 hours after the first inoculation of the transfected exosomes using the 
Widefield Microscope Thermo EVOS FL and an MTT assay was performed the 
following day. Cell imaging (Figure 27) showed less cells and signs of apoptosis when 
cells were treated with the targeting plasmid encoding DTA. This was confirmed by the 
MTT cell viability results (Figure 28), indicating that one inoculation was sufficient to 





Signs of apoptosis were detected in all cells treated with the exosome mediated DTA 
gene therapy and more cells were detected in the control cells. The red fluorescence 
signal in the control cells indicated a successful uptake of the mCherry transfected 
exosomes by the glioblastoma cells. The MTT assay showed a substantially decreased 
viability of the cells treated with the exosomes containing the DTS-pIL13RA2s-DTA 
plasmids compared to that of the control cells (Figure 26 and 28). The viability of the 
DTA exosome therapy ranged from 29% to 38% and therefore, resulted in a substantial 
difference compared to the control cells in each experiment. These results 
demonstrate the efficacy of the exosome mediated DTA therapy. Also, in this case we 
cloned the DTS-pIL13RA2s-DTA plasmid into the miniplasmid pUCmu to increase the 
transfection efficiency by decreasing the plasmid size. We also subsequently studied 
the efficacy of the combination therapy using exosomes containing both the pUCmu-
DTS-pIL13RA2s-DTA and pUCmu-DTS-hpmir21-dGzmB + NLS 3x plasmids.  
3.4.6 Combination therapy with Granzyme B and Diphtheria toxin fragment A indicates 
synergistic effect on glioblastoma cells  
 
We treated the BT12 cells with a combination of exosomes containing both the 
pUCmu-DTS-pIL13RA2s-DTA and pUCmu-DTS-hpmir21-dGzmB + NLS 3x targeting 
plasmids. Untreated cells, cells incubated with PBS and three additional conditions 
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were used as controls. In these additional controls, one of the components (exosomes, 
plasmid and transfection reagent Fugene HD) was each left out. Each treatment was 
performed in triplicate. Cell viability was determined by using the MTT assay 96 hours 
after the inoculation of the transfected exosomes. The MTT assay showed none or 
only minor effect on cell viability with any of the control conditions, while the viability of 
the cells treated with the combination therapy with Granzyme B and Diphtheria toxin 
fragment A was reduced to about 75% (Figure 29). 
 
This experiment was repeated to validate the results. The second experiment showed 
very similar results than the first one with one exception. The control containing the 
transfection reagent Fugene HD and exosomes with left out plasmids decreased cell 
viability by approximately 27% (Figure 30). The viability of cells treated with the 
combination therapy was decreased by around 43% (Figure 30). While there was a 
deviation from the first experiment, the difference between the viability of cells treated 
with the combination therapy and the lowest cell viability of any of the controls 





The single treatment of targeting plasmid encoding GzmB showed a cell viability 
decrease of 11 to 19% compared to the control condition after one exosome 
inoculation. Meanwhile, the combination treatment in cells decreased the cell viability 
by 29,4% after one inoculation, indicating a synergistic effect of the targeting plasmids 
encoding GzmB and DTA.  
The average of the MTT assays for the combination therapy was calculated and is 
displayed in Figure 31. All in all, results clearly demonstrate that the combination 
therapy resulted in a decreased cell viability of 70.6% with one inoculation. The control 
conditions showed stable results with only minor decreases in cell viability, hereby 
proving that neither any potential external plasmid outside of the exosomes nor the 
toxicity of the transfection reagent Fugene HD or any passive diffusion of the plasmids 
into the exosomes was responsible for the decrease in cell viability in the gene therapy 
condition (Figure 31). 
The data obtained from the experiments was analyzed and an ANOVA test was 
performed to test for the significance of the data. The ANOVA test results are shown 
in Appendix C. The ANOVA test and the t-test both showed that the data for the 
combination therapy was significant when compared to the control conditions. Overall, 
it was proven that the set-up with exosomes isolated from HEK293FT cells and the 






















4.1 Limited efficiency of gene therapy targeting common alterations in glioblastoma 
cells due to elevated plasmid size 
 
The plasmids used to inhibit the expression of the oncogene EGFRvIII and 
overexpress the tumor suppressor genes TP53 and PTEN were utilized with the goal 
of targeting the most common alterations in glioblastoma cells and thereby decreasing 
the cell proliferation and increasing apoptotic cell death. All the plasmids were 
approximately 5700 bp and therefore significantly larger than the RNAi that has been 
delivered by exosomes prior to this project (Lozada-Delgado et al., 2017). Examples 
of the research done with exosomes is a study introducing siRNAs in exosomes 
derived from dendritic cells by electroporation with the aim of reducing the gene 
expression of a therapeutic target in Alzheimer´s disease. The results showed 
approximately 60% reduction in mRNA and protein expression of the therapeutic target 
(Sancho-Albero et al., 2020). A different study focused on isolating exosomes from 
immature dendritic cells, which were derived from the bone marrow of mice and 
subsequently the exosomes were used to deliver siRNA in vitro and in vivo in a 
targeted manner (Jiang & Gao, 2017). Additionally, it was demonstrated that modifying 
the membrane of exosomes with the aim of enhancing the targeting efficiency is 
possible. A protein targeting neurons was expressed on the surface of exosomes and 
following the intravenous injection of the exosomes in mice, the exosomes succeeded 
in reducing specific gene expression in the brain (Jiang & Gao, 2017). An additional 
study proved that exosomes can deliver exogenous miRNAs and thereby elicit a 
biological response in recipient cells (EL Andaloussi et al., 2013). These findings 
demonstrate the potential of loading RNA into exosomes with the aim of developing a 
targeted therapy in cancer or neurologic disorders, such as Alzheimer disease. 
However, these studies also display the current focus on the exosome uptake of 
smaller molecules, such as RNA, while there is a lack of research for exosomes taking 
up plasmid DNA. Due to the limited size of exosomes and the size-dependent 
transfection efficiency, a reduction in the transfection efficiency was anticipated when 
using larger plasmid DNA. Following the first inoculation of the transfected exosomes 
targeting common genetic alterations in glioblastoma cells, only approximately 20 – 
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30% of cells treated with the targeting plasmids showed signs of apoptosis and 
decreased proliferation, while an equal number of cells treated with the control 
plasmids encoding fluorescent proteins, successfully showed fluorescent signal. As a 
result of this outcome, a second inoculation was performed, which only slightly 
increased the visible apoptotic and fluorescent signal in the cells. After a third and final 
inoculation of transfected exosomes into the cells, the targeted cells showed strong 
apoptotic signal and the fluorescent signal in the control cells increased to 
approximately 60%. However, three inoculations required a large number of 
transfected exosomes, that were inoculated in a single well of a 96-well plate, hereby 
making a potential transfer to in vivo experiments unlikely. Consequently, the decision 
was made to utilize cytotoxins, which are known to induce apoptosis in cancer cells 
with the aim of increasing the efficiency of the treatment with a smaller number of 
inoculations. 
4.2 Cloning the targeting plasmids containing cytotoxins into miniplasmid pUCmu 
increased the transfection efficiency  
 
The treatment was started with the targeting plasmid hpmir21-dGzmB in the patient-
derived glioblastoma cell line BT12, resulting in cell death in the targeted cells after 
two inoculations during imaging. Consequently, to enhance the efficiency of the GzmB 
plasmid and thereby the treatment outcome, the NLS and DTS sequences were added 
to the GzmB plasmid, resulting in an increased uptake of the GzmB plasmid in the 
nucleus of the target cells. The MTT assay following the treatment showed an 80% 
decreased cell viability for the gene therapy treated cells after one inoculation, thereby 
increasing the treatment efficiency compared to the gene therapy targeting the 
glioblastoma cell alterations. Furthermore, it was decided to reduce the plasmids in 
size due to the size-dependent transfection efficiency (Hardee et al., 2017). After 
cloning the GzmB plasmid into the miniplasmid pUCmu, the resulting plasmid construct 
pUCmu-DTS-hpmir21-dGzmB + NLS 3x was decreased in size by 600 bp to a total 
size of 3388 bp. Following the molecular cloning, another reduction of the cell viability 
in the gene therapy set-up could be seen. In total, cell viability decreased by 93,1% in 
the treated condition after one inoculation, thus displaying the important correlation 
between the construct size and the transfection efficiency.  
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As a result of this promising outcome, the DTA plasmid was cloned into the miniplasmid 
pUCmu as well, with the size of the final plasmid construct pUCmu-DTS-pIL13RA2s-
DTA being reduced to 3828 bp by removing approximately 600 bp. The DTA plasmid 
was used due to its proven inhibition of the protein synthesis, resulting in apoptosis in 
cancer cells (Shafiee et al., 2019). While a plasmid-based expression of DTA in 
exosomes has not been shown so far, DTA has been used in a variety of studies.  
A study researching gene therapy for hepatocellular carcinoma assessed the efficiency 
of the DTA-expressing plasmid in vivo, by hydrodynamically delivering the naked 
plasmid DNA to the mouse liver. The results indicate the inhibition of the protein 
synthesis, apoptotic changes and the antitumor effect of the DTA expression in the 
mouse model (Kamimura et al., 2020). For the therapy of transitional cell carcinoma 
(TCC) bladder carcinoma, a strategy was developed resulting in the DTA expression 
driven by the IGF2 P3 and P4 human promoters, which have been shown to be 
particularly active in various human cancers. The results showed a 70% inhibited 
growth rate of the developed tumors in the treated human carcinoma cell lines following 
intratumorally injection (Ayesh et al., 2003). In a recent study, DTA was used for the 
delivery of siRNAs for the first time with the toxin-based delivery of siRNA resulting in 
gene downregulation in patient-derived glioblastoma cells (Arnold et al., 2020). 
Another study focused on the development of a new therapeutic approach in ovarian 
cancer cells with the aim of targeting the DTA expression under the control of H19 
regulatory sequences. H19 RNA has been detected in abundance in ovarian cancer 
and other human cancer tissues, however it is almost undetectable in healthy tissue. 
DTA-H19 was injected intratumorally into developed tumors and resulted in a 40% 
inhibition of tumor growth (Mizrahi et al., 2009). These findings display the toxicity of 
the Diphtheria toxin and its efficiency in the therapy of varying cancer types. Our gene 
therapy set-up with DTA in exosomes resulted in cell viability ranging from 29% to 38% 
when compared to the control cells and thereby succeeded in demonstrating the 
efficacy of the exosome mediated DTA therapy. 
4.3 Induction of the death of target cells was due to the plasmids outside of the 
exosomes 
 
To study the potential effect of external plasmids on the target cells, the DNAse I 
enzyme was used in the process of inoculation of the transfected exosomes into the 
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cells. Here, it was discovered that the cell viability decreases only by approximately 15 
to 20% in the targeted cells compared to the control cells, which was a reduction from 
the 93,1% without the DNAse I addition. Hence, these findings were a strong indicator 
that the apoptotic effect in the glioblastoma cells was not only due to the transfected 
exosomes but also external plasmids, that had not been taken up by the exosomes.  
The results of this project indicate that the DNAse I enzyme was successful in removing 
external plasmid, since the cells treated with the gene therapy and without the addition 
of exosomes did not show any decrease in cell viability at all. This suggests that the 
20% decrease in cell viability in the target cells are solely due to the exosome-based 
gene therapy.  
A study revealed that loading short linear double stranded DNA (dsDNA) into 
extracellular vesicles by electroporation with the addition of DNAse I enzyme resulted 
in the degradation of the majority of DNA, associated with the extracellular vesicles. 
However, on average hundreds of copies of DNA per extracellular vesicle still remained 
(Lamichhane et al., 2015). These findings would explain the difference in cell viability 
decrease that was seen after the addition of the DNAse I enzyme and further 
encourage that the decrease in cell viability in the treated cells with the addition of the 
DNAse I enzyme occurred due to the remaining exosome-based gene therapy. 
However, it has to be noted that the DNA loading method into the exosomes differed 
and the plasmid DNA used in this project had an average size of 3500 bp, while the 
study used a 250 bp dsDNA.  
4.4 Potential toxicity of chemical transfection reagent Fugene HD on glioblastoma cells  
 
While optimizing the varying conditions in glioblastoma cells to determine the causes 
for the decreased cell viability, it was observed that while the majority of the control 
cells showed reproducible results, the transfection reagent Fugene HD and exosomes 
displayed variable results. These variations were also noted in experiments that 
included exosomes and plasmid. Since the transfection reagent seemed likely to be 
the reason for this non-specific behavior, the ratio of Fugene-Plasmid was reduced 
from a 1:4 to a 1:3 ratio, which resulted in a reduction of the toxicity related to the 
Fugene HD but failed to completely erase the variations in cell viability over the courses 
of several experiments. Studies have shown that commercial transfection reagents can 
be used to introduce siRNA or other genetic material into exosomes but the 
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electroporation method resulted in a higher efficiency of transfected exosomes 
compared to the transfection method (Jiang & Gao, 2017). As a consequence of the 
comparably low efficiency of the transfection method, we researched alternative 
methods for loading DNA into exosomes.  
Recent studies showed the varying exogenous techniques for loading plasmids into 
extracellular vesicles, such as transfection, electroporation, and sonication (Orefice, 
2020). The transfection method used in this study is simple to use and delivers a good 
plasmid DNA concentration. However, the disadvantages include that the transfection 
reagent could get partly hooked and the vesicle membranes might show deformations. 
Another disadvantage is the poor efficacy to transfect cells grown in suspension. 
Therefore, it was decided to use the alternative plasmid DNA loading method, 
electroporation, which comes with several advantages. These include loading of larger 
plasmid DNA and transfection of hard-to-transfect cells. Further, electroporation is 
quite versatile and results in direct uptake of the plasmid into the cells. While these 
advantages are beneficial to the experiments, there are also disadvantages that are 
connected to the electroporation, such as the potential damage of the cells and the 
possibility that the electroporation might result in an aggregation of the extracellular 
vesicles and thus alter the morphological characteristics of the exosomes (Orefice, 
2020). A third alternative method would be sonication, which shows an increased 
loading efficiency and no chemical reagents are used in the process. However, during 
sonication the membrane could potentially get deformed through overheating and this 
method is only applicable to smaller sized plasmid DNA (Orefice, 2020). Hence, these 
limitations should be regarded, when selecting the transfection method. 
Alternative methods to upload plasmid DNA into exosomes have been tested in the 
lab, such as electroporation, however, Fugene-HD has shown to be the most effective. 
The drawbacks of the electroporation method might be the reason, why electroporation 
has failed to show an increased efficiency compared to the transfection method with 
Fugene HD. In addition, studies have shown that electroporation has been successful 
for loading smaller molecules, such as siRNAs into extracellular vesicles (Lamichhane 
et al., 2015). However, loading DNA into exosomes has been associated with 
limitations due to the increased size and therefore primarily transfection-based 
approaches have been used so far (Lamichhane et al., 2015). These findings are 
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consistent with our research and therefore work is ongoing to minimize the toxic effects 
of the transfection reagent on cell viability. 
4.5 OP9 cell derived exosomes are more efficient in cell killing than the HEK293FT cell 
derived exosomes 
 
While the set-up of the exosome-based gene therapy was conducted using the 
HEK293FT cells as the source of the exosomes, one experiment was performed with 
virus transduced murine stem cell OP9 derived exosomes to study the efficiency of 
these delivery vesicles. In theory, these exosomes should result in a higher efficacy 
due to the engineered expression of the homing peptide iRGD on the surface of the 
exosomes. The homing peptide iRGD results in an improved targeting of the cancer 
cells and a better uptake of the exosomes into the glioblastoma cells, thereby 
increasing the efficiency of the gene therapy on the target cells. 
The results showed a decrease in cell viability in both control and treated cells, which 
differed from the results obtained with the HEK293 derived exosomes, which did not 
show any or only a minor decrease in viability of control cells, while the treated cells 
showed reproducible results with 15 - 20% reduction in cell viability. In case of the OP9 
derived exosomes, the viability of control cells decreased by approximately 40% while 
the cell viability of treated cells decreased by approximately 55%. Thus, the 15% 
increased cell death of treated cells compared to the control cells is similar to the 
results obtained using the HEK293FT derived exosomes. So far, there is no clear 
explanation for the strong decrease in cell viability in the control cells using the OP9 
derived exosomes, but further experiments including the OP9 derived exosomes 
should provide insight into the potential mechanisms behind this.  
4.6 Combination therapy results in the highest efficacy in glioblastoma cells 
 
The targeting plasmid pUCmu-DTS-hpmir21-dGzmB + NLS 3x showed a reproducible 
15 – 20% decrease in cell viability after one inoculation in the glioblastoma cell line 
BT12, which had been proven to be due to the exosome-based gene therapy. The 
combination therapy, resulting in the GzmB and DTA expression in the target cells 
demonstrated a 29,4% decrease in cell viability in the treated cells, while none or only 
minor effect was detected in the control cells. Even though the efficiency of the 
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chemical transfection utilizing the transfection reagent Fugene HD is generally quite 
low, the efficiency of the combination therapy was proven to be significant in this set-
up. Thus, the combination therapy resulted in an additional 10 to 15% decrease in the 
viability of target cells and therefore it was the most efficient approach for the gene 
therapy in this study.  
At the moment, no in-depth research is available for the use of exogenous plasmid 
DNA in extracellular vesicles (Orefice, 2020). Therefore, there are no publications 
concerning this strategy and the combination plasmid-based therapy in exosomes 
displays a novel set-up for the use of plasmid DNA in exosomes.   
4.7 Advantages of exosome-based gene therapy utilizing targeting plasmids in 
glioblastoma cells  
 
Several advantages are connected to the use of exosomes as the carriers for the gene 
therapy in glioblastoma cells. These include their availability, the decreased probability 
of immune reactions, the option of repeated administration of exosomes and their cost-
effectiveness compared to the virus-derived vectors (Orefice, 2020). Thus, using 
exosomes as shuttles to transfer gene therapy to the cancer cells results in a 
decreased risk of immune reactions and toxicity and therefore increases the safety of 
the treatment. However, research is still limited when it comes to the ability of 
exosomes to take up plasmid DNA due to the limited exosomes size (Orefice, 2020). 
So far, double stranded DNA oligonucleotides such as plasmids have not been used 
for an exosome-based gene therapy since an increase of the size would negatively 
influence the transfection efficiency. By cloning the plasmid constructs into the 
miniplasmid pUCmu, the plasmid size was reduced, making it possible to transfect 
plasmids into exosomes and still perform an efficient transfection. 
This project focused on a plasmid-based gene therapy due to their numerous 
advantages in the regulation of gene expression. Exosomes have the ability to target 
other cell types in addition to glioblastoma cells and the combination gene therapy, 
which was used in this project is nonspecific, allowing targeting of different cell types. 
However, the uptake of exosomes might vary for different cancer types, since the 
mechanisms used for the exosome uptake are dependent on the recipient cells (Horibe 
et al., 2018). Due to the use of plasmids in this project, a conditional expression was 
possible, which is not the case when RNA is used as the gene therapy. Conditional 
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expression is a vital concept for the safety of the plasmid-based gene therapies in 
exosomes by minimizing the side effects and increasing the safety of this set-up. This 
is achieved by using promoters that are particularly active and thereby show a 
conditional expression in cancer cells. Therefore, healthy cells, targeted by the 
transfected exosomes should not express the therapy and should not be damaged. 
Glioblastoma cells, on the other side have active promoters, resulting in expression of 
the therapy when targeted by the transfected exosomes creating a safe approach for 
the in vivo preclinical studies and future possible applications in patients.  
Furthermore, using plasmids for the gene therapy enabled the finetuning of the plasmid 
expression by addition of enhancing sequences, such as the DNA translocation 
sequence (DTS) and the nuclear localization sequence (NLS), which were added to 
the Granzyme B plasmid to enhance the gene transcription and the uptake into the 
nucleus, where the damage took place. Additionally, control plasmids could be 
constructed, carrying sequences for fluorescent proteins, which was used to study the 
uptake of the transfected exosomes into the target cells. Overall, the possibility of 
finetuning and regulating the conditional expression are the main advantages of using 
plasmids in the exosome-based gene therapy.  
4.8 Potential next steps in the research project  
 
The efficiency of the combination therapy could potentially be increased by further 
optimizing the components of the set-up exosome-based gene therapy, such as the 
transfection reagent Fugene HD and the enzyme DNAse I. Determining a set amount 
of the transfection reagent Fugene HD could potentially lead to a reduction of the 
unspecific toxicity. In addition, the optimization of the DNAse I enzyme amount needed 
to remove the plasmid outside of the exosomes, while not damaging the target cells, 
might improve the efficacy of the combination therapy. To achieve this, an experiment 
could be set up, titrating the amount of DNAse in a control condition without exosomes 
and a treated condition with exosomes, followed by an imaging check-up of the cells 
and an MTT assay to confirm the results.  
Additionally, the number of exosomes added for one inoculation and varying plasmid 
amounts could be studied, to define the optimal conditions for the exosome-based 
gene therapy set-up. 
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Furthermore, the combination therapy resulted in a significant decrease in cell viability 
in the treated cells after one inoculation, thereby entailing a potential increase of the 
treatment efficiency following additional inoculations. Consequently, the number of 
inoculations needs to be increased to study the efficiency of several inoculations. The 
combination therapy was only studied for one inoculation, which led to a decrease in 
cell variability of approximately 30%. Nevertheless, more inoculations would probably 
be required to result in at least 70% decrease in cell viability of the target cells. To 
achieve that, either two inoculations could be performed over the span of eight days, 
or two inoculations could be carried out at the same time point with an endpoint of the 
experiment after four days. In case this approach fails to improve the efficacy, a novel 
gene therapy with plasmids encoding different apoptosis inducing proteins could be 
studied in this experimental set-up.  
After optimizing the experimental components and increasing the number of 
inoculations, the subsequent step would consist of repeating the set-up in other 
patient-derived glioblastoma cells.  
Following the successful efficacy of the exosome-based gene therapy in at least two 
different glioblastoma cell lines, the next step in the project would include setting up 
the therapy for exosomes isolated from the virus transfected mesenchymal murine 
progenitor OP9 cell line.  
While exosomes carry many receptors, due to the virus transduction, the exosomes 
isolated from the OP9 cells were equipped with an additional homing peptide receptor, 
the iRGD peptide (Yin et al., 2017). This iRGD homing peptide on the surface of the 
exosomes allows specific targeting of cancer cells and therefore should enhance the 
targeting of the glioblastoma cells (Yin et al., 2017). The enhanced targeting was not 
seen in the results, since the decrease in cell viability was similar to the decrease 
shown by HEK293FT derived exosomes. However, the results showed that the OP9 
derived exosomes resulted in a strong toxicity in control and treated cells, which might 
be a reason for the lack of enhanced targeting efficiency. With additional research and 
further optimization of the OP9 derived exosomes, this problem could potentially be 
resolved.  
Subsequently, the exosome-based gene therapy could be tested in in vivo preclinical 
models of glioblastoma to assess the efficacy.  
70 
 
4.9 Future opportunities  
 
Glioblastoma continues to show a poor prognosis associated to low survival rates, 
which can be connected to its heterogenous histology, invasiveness and recurrent 
nature (Bălașa et al., 2020), along with a resistance to the conventional therapy 
approaches (Tang et al., 2019). Though the treatment for glioblastoma was continually 
improved in recent years, it is not possible to cure this cancer type yet (Hanif et al., 
2017), with the therapy being mostly palliative (Kesari, 2011). In recent years, the 
increasing understanding behind the molecular mechanisms of glioblastoma 
development and progression has opened the door to new personalized treatment 
approaches (Bălașa et al., 2020), which are urgently needed.  
So far, mRNA-based therapeutic models seem promising due to their many 
advantages, such as simple manipulation, fast expression and adaptive nature without 
mutagenesis, thereby being an optimal candidate for addressing the complex and 
variable nature of glioblastoma (Tang et al., 2019). Viruses have been used as one of 
the main delivery vehicles for the gene therapy, but in recent years, other alternative 
carriers have started to emerge (Kwiatkowska et al., 2013). Exosomes have shown 
many valuable advantages when compared to virus vectors and thus have started to 
become a promising new research subject for the delivery of gene therapies in cancer.  
This study focused on a plasmid-based gene therapy in exosomes, which has not been 
used in therapeutic research in glioblastoma yet, but nevertheless facilitates 
conditional expression and finetuning of plasmids, thereby showing an important 
advantage compared to the mRNA-based therapeutic models. By setting up a plasmid-
based gene therapy in exosomes for glioblastoma cells, the concept of this potentially 
new therapeutic model was proven, which could be further researched as a novel 
targeted therapy approach in glioblastoma cells.  
Overall, this research project has shown a successful proof-of-concept by constructing 
a working plasmid-based gene therapy, delivered by exosomes. The exosomes then 
transfer these plasmids into target cells, decreasing the cell viability. Since the proof of 
principle is completed, the next step requires additional studying, finetuning and further 




5 Acknowledgments  
 
To Pirjo: Thank you for giving me the opportunity to conduct my master thesis in such 
an interesting research area in your lab and for your constant support and joyful lab 
atmosphere. The past year has been such a great experience full of wonderful 
memories and I am fully aware that I couldn’t have picked a better lab for my thesis.  
To Hector: Thank you for taking me as your master student last year and giving me 
the chance to be a part of this interesting project, even though my experience with 
exosomes was limited. I learned so much from you during this year and I am still 
amazed at how patient and supportive you were. This last year was so much fun and 
you and JK were such a big part of that. Thank you so much for being the best 
supervisor any student could ask for!  
To JK: I really appreciate how much I learned from you about science, pipettes and 
western blots and I especially value how many times you made the effort to support 
me. It meant a lot to me, when you helped me with my thesis plan back in August as 
well as when you attended my thesis defense, even though you were already 
occupied. You were an amazing supervisor and a big part of our little lab family with 
Hector and Sara. Thank you for all the big and small moments with you, that will 
always make me smile when I think of them!  
To Sara: You have been a constant in my life for the duration of my master´s thesis 
and you made this time a million times better. Thank you for being by my side for so 
many exosome isolations (for which you did an uncountable amount of column 
washes) and all of our conversations in and out of the lab and for making me laugh, 
even when I was tired. Just seeing you in the morning, when I came to the lab made 
my day and I know that our friendship will continue long after we both submitted our 
thesis. You are a truly amazing friend and I am so thankful to this group for bringing 
us together. We share so many great memories working alongside each other day 
and night in the lab and we always pushed each other to the limits. You were also the 
first person to talk to when I wanted to experience the Finnish way of life including 
Finnish recipes. I cannot wait for all the wonderful experiences still to come.  
To the Laakkonen Lab members: Thank you Pauliina, Vadim, Rym, Onerva and Abi 
for your helpful advice during the lab meetings and for being such great supportive 
colleagues in the lab. A special thank you to Vadim for teaching me new skills with 
72 
 
mice after receiving my animal license and to Abi for brightening up many lab days by 
joking around with us but also for sharing a lot of valuable advice for our future. I truly 
enjoyed the time in the lab with you and I hope, that at some point once the 
pandemic is over, we get to do something fun together outside of the lab.  
To Tiina Immonen: Thank you for your constant support especially during my first few 
weeks at the University of Helsinki. I really valued all your helpful advice. 
To my TRANSMED colleagues: Thank you for all of the great times we had together, 
ranging from crayfish parties over kotiapprot to many memorable party nights! I never 
imagined to be part of a study program, in which everybody was so much fun to be 
around and even long lectures were a great thing, because it meant to spend time 
with all of you. Choosing this program has been one of the best choices I have ever 
made and meeting all of you is a big reason for that!  
To my parents Silke & Dursun: I know that it was tough for you to let me move to a 
different country for two more years, after I had already spent my bachelor in 
Potsdam, many miles from home. It means the world to me, that even though my 
decision led to me missing many events and important moments, you still supported 
me with all you could give. If I am sure of one thing, it´s that you are proud of what I 
have achieved these past years and that you truly believe in me and for this, I wanted 
to say thank you to both of you! Especially a big thanks to my mum for always 
reminding me, that Germany has better weather and more sunlight. That really 
helped while trying to survive the Finnish winter. Ich liebe euch beide sehr! Danke für 
alles!  
To my dearest twin sister Vanessa: Thank you for always being by my side, for being 
my greatest cheerleader and for your unwavering belief that I will always exceed in 
life, no matter what I do. You are the one, I can always talk to and you manage to 
make me laugh, even after the longest and most exhausting days. I know I wouldn´t 
be where I am without you. You are such a big part of who I am and witnessing your 
discipline in your law studies makes me want to be better in life and encourages me 
to work harder every day. Thank you for our constant Skype calls, which always last 
for hours and make me feel like you are right there beside me. Being apart from you 
for these past 6 years has been incredibly hard and I look forward to the coming 
months and years with you, in which we will hopefully spend a lot of time by each 





Addgene 2019, Generating Stable Cell Lines with Lentivirus, accessed 22 April 2021, 
<https://www.addgene.org/protocols/generating-stable-cell-lines/> 
Alifieris, C., & Trafalis, D. T. (2015). Glioblastoma multiforme: Pathogenesis and 
treatment. In Pharmacology and Therapeutics. 
https://doi.org/10.1016/j.pharmthera.2015.05.005 
Arnold, A. E., Smith, L. J., Beilhartz, G., Bahlmann, L. C., Jameson, E., Melnyk, R., & 
Shoichet, M. S. (2020). Attenuated diphtheria toxin mediates siRNA delivery. 
Science Advances. https://doi.org/10.1126/sciadv.aaz4848 
Ayesh, B., Matouk, I., Ohana, P., Sughayer, M. A., Birman, T., Ayesh, S., Schneider, 
T., de Groot, N., & Hochberg, A. (2003). Inhibition of tumor growth by DT-A 
expressed under the control of IGF2 P3 and P4 promoter sequences. Molecular 
Therapy. https://doi.org/10.1016/S1525-0016(03)00056-X 
Bălașa, A., Șerban, G., Chinezu, R., Hurghiș, C., Tămaș, F., & Manu, D. (2020). The 
involvement of exosomes in glioblastoma development, diagnosis, prognosis, 
and treatment. In Brain Sciences. https://doi.org/10.3390/brainsci10080553 
Bastos, N., Ruivo, C. F., da Silva, S., & Melo, S. A. (2018). Exosomes in cancer: Use 
them or target them? In Seminars in Cell and Developmental Biology. 
https://doi.org/10.1016/j.semcdb.2017.08.009 
Batash, R., Asna, N., Schaffer, P., Francis, N., & Schaffer, M. (2017). Glioblastoma 
Multiforme, Diagnosis and Treatment; Recent Literature Review. Current 
Medicinal Chemistry. https://doi.org/10.2174/0929867324666170516123206 
Benitez, J. A., Ma, J., D’Antonio, M., Boyer, A., Camargo, M. F., Zanca, C., Kelly, S., 
Khodadadi-Jamayran, A., Jameson, N. M., Andersen, M., Miletic, H., Saberi, S., 
Frazer, K. A., Cavenee, W. K., & Furnari, F. B. (2017). PTEN regulates 
glioblastoma oncogenesis through chromatin-associated complexes of DAXX 
and histone H3.3. Nature Communications. 
https://doi.org/10.1038/ncomms15223 
Chandramohan, V., Sampson, J. H., Pastan, I., & Bigner, D. D. (2012). Toxin-based 
targeted therapy for malignant brain tumors. In Clinical and Developmental 
Immunology. https://doi.org/10.1155/2012/480429 
Clarke, J., Butowski, N., & Chang, S. (2010). Recent advances in therapy for 
glioblastoma. In Archives of Neurology. 
https://doi.org/10.1001/archneurol.2010.5 
Davis, H. E., Morgan, J. R., & Yarmush, M. L. (2002). Polybrene increases retrovirus 
gene transfer efficiency by enhancing receptor-independent virus adsorption on 
target cell membranes. Biophysical Chemistry. https://doi.org/10.1016/S0301-
4622(02)00057-1 
Davis, M. E. (2016). Glioblastoma: Overview of disease and treatment. Clinical 
Journal of Oncology Nursing. https://doi.org/10.1188/16.CJON.S1.2-8 
De Toro, J., Herschlik, L., Waldner, C., & Mongini, C. (2015). Emerging roles of 
exosomes in normal and pathological conditions: New insights for diagnosis and 
74 
 
therapeutic applications. In Frontiers in Immunology. 
https://doi.org/10.3389/fimmu.2015.00203 
EL Andaloussi, S., Lakhal, S., Mäger, I., & Wood, M. J. A. (2013). Exosomes for 
targeted siRNA delivery across biological barriers. In Advanced Drug Delivery 
Reviews. https://doi.org/10.1016/j.addr.2012.08.008 
G. Castro, M., Candolfi, M., M. Kroeger, K., D. King, G., F. Curtin, J., Yagiz, K., 
Mineharu, Y., Assi, H., Wibowo, M., K.M. Ghulam Muhammad, A., Foulad, D., 
Puntel, M., & R. Lowenstein, P. (2011). Gene Therapy and Targeted Toxins for 
Glioma. Current Gene Therapy. https://doi.org/10.2174/156652311795684722 
Gallego, O. (2015). Nonsurgical treatment of recurrent glioblastoma. In Current 
Oncology. https://doi.org/10.3747/co.22.2436 
Gilligan, K. E., & Dwyer, R. M. (2017). Engineering exosomes for cancer therapy. In 
International Journal of Molecular Sciences. 
https://doi.org/10.3390/ijms18061122 
Gourlay, J., Morokoff, A. P., Luwor, R. B., Zhu, H. J., Kaye, A. H., & Stylli, S. S. 
(2017). The emergent role of exosomes in glioma. In Journal of Clinical 
Neuroscience. https://doi.org/10.1016/j.jocn.2016.09.021 
Grech, N., Dalli, T., Mizzi, S., Meilak, L., Calleja, N., & Zrinzo, A. (2020). Rising 
Incidence of Glioblastoma Multiforme in a Well-Defined Population. Cureus. 
https://doi.org/10.7759/cureus.8195 
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. In Cell. 
https://doi.org/10.1016/S0092-8674(00)81683-9 
Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M., & Simjee, S. U. (2017). 
Glioblastoma multiforme: A review of its epidemiology and pathogenesis through 
clinical presentation and treatment. In Asian Pacific Journal of Cancer 
Prevention. https://doi.org/10.22034/APJCP.2017.18.1.3 
Hardee, C. L., Arévalo-Soliz, L. M., Hornstein, B. D., & Zechiedrich, L. (2017). 
Advances in non-viral DNA vectors for gene therapy. In Genes. 
https://doi.org/10.3390/genes8020065 
Hehmann-Titt, G., Schiffer, S., Berges, N., Melmer, G., & Barth, S. (2013). Improving 
the Therapeutic Potential of Human Granzyme B for Targeted Cancer Therapy. 
Antibodies. https://doi.org/10.3390/antib2010019 
Horibe, S., Tanahashi, T., Kawauchi, S., Murakami, Y., & Rikitake, Y. (2018). 
Mechanism of recipient cell-dependent differences in exosome uptake. BMC 
Cancer. https://doi.org/10.1186/s12885-017-3958-1 
Jiang, X. C., & Gao, J. Q. (2017). Exosomes as novel bio-carriers for gene and drug 
delivery. In International Journal of Pharmaceutics. 
https://doi.org/10.1016/j.ijpharm.2017.02.038 
Kalluri, R., & LeBleu, V. S. (2020). The biology, function, and biomedical applications 
of exosomes. In Science (Vol. 367, Issue 6478). 
https://doi.org/10.1126/science.aau6977 
Kamimura, K., Yokoo, T., Abe, H., Sakai, N., Nagoya, T., Kobayashi, Y., Ohtsuka, M., 
Miura, H., Sakamaki, A., Kamimura, H., Miyamura, N., Nishina, H., & Terai, S. 
75 
 
(2020). Effect of diphtheria toxin-based gene therapy for hepatocellular 
carcinoma. Cancers. https://doi.org/10.3390/cancers12020472 
Kesari, S. (2011). Understanding glioblastoma tumor biology: The potential to 
improve current diagnosis and treatments. Seminars in Oncology. 
https://doi.org/10.1053/j.seminoncol.2011.09.005 
Kwiatkowska, A., Nandhu, M., Behera, P., Chiocca, E., & Viapiano, M. (2013). 
Strategies in Gene Therapy for Glioblastoma. Cancers. 
https://doi.org/10.3390/cancers5041271 
Lamichhane, T. N., Raiker, R. S., & Jay, S. M. (2015). Exogenous DNA loading into 
extracellular vesicles via electroporation is size-dependent and enables limited 
gene delivery. Molecular Pharmaceutics. 
https://doi.org/10.1021/acs.molpharmaceut.5b00364 
Le Joncour, V., Filppu, P., Hyvönen, M., Holopainen, M., Turunen, S. P., Sihto, H., 
Burghardt, I., Joensuu, H., Tynninen, O., Jääskeläinen, J., Weller, M., Lehti, K., 
Käkelä, R., & Laakkonen, P. (2019). Vulnerability of invasive glioblastoma cells 
to lysosomal membrane destabilization. EMBO Molecular Medicine. 
https://doi.org/10.15252/emmm.201809034 
Li, X., Corbett, A. L., Taatizadeh, E., Tasnim, N., Little, J. P., Garnis, C., Daugaard, 
M., Guns, E., Hoorfar, M., & Li, I. T. S. (2019). Challenges and opportunities in 
exosome research—Perspectives from biology, engineering, and cancer 
therapy. APL Bioengineering. https://doi.org/10.1063/1.5087122 
Lin, Y., Wu, J., Gu, W., Huang, Y., Tong, Z., Huang, L., & Tan, J. (2018). Exosome–
Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. 
Advanced Science. https://doi.org/10.1002/advs.201700611 
Liu, C., & Su, C. (2019). Design strategies and application progress of therapeutic 
exosomes. In Theranostics (Vol. 9, Issue 4). https://doi.org/10.7150/thno.30853 
Lozada-Delgado, E. L., Grafals-Ruiz, N., & Vivas-Mejía, P. E. (2017). RNA 
interference for glioblastoma therapy: Innovation ladder from the bench to clinical 
trials. In Life Sciences. https://doi.org/10.1016/j.lfs.2017.08.027 
Martinez, R., Schackert, G., Yaya-Tur, R., Rojas-Marcos, I., Herman, J. G., & 
Esteller, M. (2007). Frequent hypermethylation of the DNA repair gene MGMT in 
long-term survivors of glioblastoma multiforme [1]. In Journal of Neuro-Oncology. 
https://doi.org/10.1007/s11060-006-9292-0 
Mizrahi, A., Czerniak, A., Levy, T., Amiur, S., Gallula, J., Matouk, I., Abu-lail, R., 
Sorin, V., Birman, T., de Groot, N., Hochberg, A., & Ohana, P. (2009). 
Development of targeted therapy for ovarian cancer mediated by a plasmid 
expressing diphtheria toxin under the control of H19 regulatory sequences. 
Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-7-69 
Montano, N., Cenci, T., Martini, M., D’Alessandris, Q. G., Pelacchi, F., Ricci-Vitiani, 
L., Maira, G., de Maria, R., Larocca, L. M., & Pallini, R. (2011). Expression of 
EGFRvIII in glioblastoma: Prognostic significance revisited. Neoplasia. 
https://doi.org/10.1593/neo.111338 
Mrugala, M. M. (2013). Advances and Challenges in the Treatment of Glioblastoma: 
A Clinician’s Perspective. Discovery Medicine. 
76 
 
New England Biolabs 2021, Gibson Assembly®, accessed 8 February 2021, 
<https://international.neb.com/applications/cloning-and-synthetic-biology/dna-
assembly-and-cloning/gibson-assembly> 
New England Biolabs 2021, NEBuilder HiFi DNA Assembly Reaction Protocol, 
accessed 13 February 2021, 
<https://international.neb.com/protocols/2014/11/26/nebuilder-hifi-dna-assembly-
reaction-protocol> 
O’Loughlin, A., Woffindale, C., & Wood, M. (2012). Exosomes and the Emerging 
Field of Exosome-Based Gene Therapy. Current Gene Therapy, O’Loughlin, A., 
Woffindale, C., Wood, M. (2012). https://doi.org/10.2174/156652312802083594 
Orefice, N. S. (2020). Development of new strategies using extracellular vesicles 
loaded with exogenous nucleic acid. In Pharmaceutics. 
https://doi.org/10.3390/pharmaceutics12080705 
Padfield, E., Ellis, H. P., & Kurian, K. M. (2015). Current therapeutic advances 
targeting EGFR and EGFRvIII in glioblastoma. Frontiers in Oncology. 
https://doi.org/10.3389/fonc.2015.00005 
Pullan, J. E., Confeld, M. I., Osborn, J. K., Kim, J., Sarkar, K., & Mallik, S. (2019). 
Exosomes as Drug Carriers for Cancer Therapy. Molecular Pharmaceutics. 
https://doi.org/10.1021/acs.molpharmaceut.9b00104 
Rousalova, I., & Krepela, E. (2010). Granzyme B-induced apoptosis in cancer cells 
and its regulation (review). In International Journal of Oncology. 
https://doi.org/10.3892/ijo-00000788 
Sancho-Albero, M., Medel-Martínez, A., & Martín-Duque, P. (2020). Use of 
exosomes as vectors to carry advanced therapies. RSC Advances. 
https://doi.org/10.1039/d0ra02414g 
Shafiee, F., Aucoin, M. G., & Jahanian-Najafabadi, A. (2019). Targeted Diphtheria 
Toxin-Based Therapy: A Review Article. In Frontiers in Microbiology. 
https://doi.org/10.3389/fmicb.2019.02340 
Sharma, A., Khatun, Z., & Shiras, A. (2016). Tumor exosomes: Cellular postmen of 
cancer diagnosis and personalized therapy. In Nanomedicine. 
https://doi.org/10.2217/nnm.15.210 
Srivastava, A., Filant, J., Moxley, K., Sood, A., McMeekin, S., & Ramesh, R. (2015). 
Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, 
Diagnosis and Treatment. Current Gene Therapy. 
https://doi.org/10.2174/1566523214666141224100612 
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. 
M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. (2009). Tissue-Penetrating 
Delivery of Compounds and Nanoparticles into Tumors. Cancer Cell. 
https://doi.org/10.1016/j.ccr.2009.10.013 
Sun, N. feng, Liu, Z. ao, Huang, W. bai, Tian, A. ling, & Hu, S. yuan. (2014). The 
research of nanoparticles as gene vector for tumor gene therapy. In Critical 




Tamimi, A. F., & Juweid, M. (2017). Epidemiology and Outcome of Glioblastoma. In 
Glioblastoma. https://doi.org/10.15586/codon.glioblastoma.2017.ch8 
Tang, X., Zhang, S., Fu, R., Zhang, L., Huang, K., Peng, H., Dai, L., & Chen, Q. 
(2019). Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma. 
In Frontiers in Oncology. https://doi.org/10.3389/fonc.2019.01208 
Wei, W., Ao, Q., Wang, X., Cao, Y., Liu, Y., Zheng, S. G., & Tian, X. (2021). 
Mesenchymal Stem Cell–Derived Exosomes: A Promising Biological Tool in 
Nanomedicine. In Frontiers in Pharmacology. 
https://doi.org/10.3389/fphar.2020.590470 
Wirsching, H. G., Galanis, E., & Weller, M. (2016). Glioblastoma. In Handbook of 
Clinical Neurology. https://doi.org/10.1016/B978-0-12-802997-8.00023-2 
Yang, J. M., Schiapparelli, P., Nguyen, H. N., Igarashi, A., Zhang, Q., Abbadi, S., 
Amzel, L. M., Sesaki, H., Quinõnes-Hinojosa, A., & Iijima, M. (2017). 
Characterization of PTEN mutations in brain cancer reveals that pten mono-
ubiquitination promotes protein stability and nuclear localization. Oncogene. 
https://doi.org/10.1038/onc.2016.493 
Yin, H., Zhang, Q., Yang, J., Wang, H., Xu, J., & Zheng, J. (2017). IRGD as a tumor-
penetrating peptide for cancer therapy (Review). In Molecular Medicine Reports. 
https://doi.org/10.3892/mmr.2017.6419 
Zhang, J., Wei, H., Guo, X., Hu, M., Gao, F., Li, L., & Zhang, S. (2012). Functional 
verification of the diphtheria toxin A gene in a recombinant system. Journal of 
Animal Science and Biotechnology. https://doi.org/10.1186/2049-1891-3-29 
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., 
Setiady, I., Deveau, C., Saoud, K., Grello, C., Oxford, M., Yuan, F., & 


















7.1 Appendix A | Gel electrophoresis pictures  
 
The gel electrophoresis pictures taken as a confirmation following the molecular 
cloning for the targeting and non-targeting plasmids are displayed in the Figures 32 – 
35.  
 
                                







7.2 Appendix B | Supplemental primer sequences 
 
 Table S1. Primer sequences used for plasmid construction.  



































































pUC ORI RV gctctgctaatcctgttaccag 
pUCmu.hpmir21-
GFP + 3x NLS 
(dGzmB) 











































































































Table S2. Primer sequences used for PCR expression check following plasmid construction. 
























DTA DTA check FW gtgagcaggaagctgttcg 63 469 
DTA check RV aagcaccatcaccgaacc 
GzmB GzmB check 
FW 





7.3 Appendix C | Supplemental One-way and Post Hoc ANOVA test report in SPSS 







Output Created 17-FEB-2021 15:40:03 
Comments  
Input Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
24 
Missing Value Handling Definition of Missing User-defined missing values 
are treated as missing. 
Cases Used Statistics for each analysis 
are based on cases with no 
missing data for any variable 
in the analysis. 
Syntax ONEWAY MTT BY Groups 
  /MISSING ANALYSIS. 
Resources Processor Time 00:00:00.02 










MTT   
 Sum of Squares df Mean Square F Sig. 
Between Groups 2838.837 5 567.767 6.293 .002 
Within Groups 1623.892 18 90.216   
Total 4462.730 23    
 
ONEWAY MTT BY Groups 
  /MISSING ANALYSIS 










Output Created 17-FEB-2021 15:42:51 
Comments  
Input Active Dataset DataSet1 
Filter <none> 
Weight <none> 
Split File <none> 
N of Rows in Working Data 
File 
24 
Missing Value Handling Definition of Missing User-defined missing values 
are treated as missing. 
Cases Used Statistics for each analysis 
are based on cases with no 
missing data for any variable 
in the analysis. 
Syntax ONEWAY MTT BY Groups 
  /MISSING ANALYSIS 
  /POSTHOC=TUKEY 
BONFERRONI ALPHA(0.05). 
Resources Processor Time 00:00:00.02 




MTT   
84 
 
 Sum of Squares df Mean Square F Sig. 
Between Groups 2838.837 5 567.767 6.293 .002 
Within Groups 1623.892 18 90.216   









Dependent Variable:   MTT   
 














Cells PBS .175 6.716 1.000 -21.17 21.52 
Fugene/Plasmid 4.775 6.716 .978 -16.57 26.12 
Fugene/Exosomes 3.675 6.716 .993 -17.67 25.02 
Exosomes/Plasmid -3.250 6.716 .996 -24.59 18.09 
Exosome/Plasmid/F
ugene 
29.400* 6.716 .004 8.06 50.74 
PBS Cells -.175 6.716 1.000 -21.52 21.17 
Fugene/Plasmid 4.600 6.716 .981 -16.74 25.94 
Fugene/Exosomes 3.500 6.716 .995 -17.84 24.84 
Exosomes/Plasmid -3.425 6.716 .995 -24.77 17.92 
Exosome/Plasmid/F
ugene 
29.225* 6.716 .004 7.88 50.57 
Fugene/Plasmid Cells -4.775 6.716 .978 -26.12 16.57 
PBS -4.600 6.716 .981 -25.94 16.74 
Fugene/Exosomes -1.100 6.716 1.000 -22.44 20.24 
Exosomes/Plasmid -8.025 6.716 .834 -29.37 13.32 
Exosome/Plasmid/F
ugene 
24.625* 6.716 .019 3.28 45.97 
Fugene/Exosomes Cells -3.675 6.716 .993 -25.02 17.67 
PBS -3.500 6.716 .995 -24.84 17.84 
Fugene/Plasmid 1.100 6.716 1.000 -20.24 22.44 
Exosomes/Plasmid -6.925 6.716 .901 -28.27 14.42 
Exosome/Plasmid/F
ugene 
25.725* 6.716 .013 4.38 47.07 
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Exosomes/Plasmid Cells 3.250 6.716 .996 -18.09 24.59 
PBS 3.425 6.716 .995 -17.92 24.77 
Fugene/Plasmid 8.025 6.716 .834 -13.32 29.37 
Fugene/Exosomes 6.925 6.716 .901 -14.42 28.27 
Exosome/Plasmid/F
ugene 
32.650* 6.716 .001 11.31 53.99 
Exosome/Plasmid/F
ugene 
Cells -29.400* 6.716 .004 -50.74 -8.06 
PBS -29.225* 6.716 .004 -50.57 -7.88 
Fugene/Plasmid -24.625* 6.716 .019 -45.97 -3.28 
Fugene/Exosomes -25.725* 6.716 .013 -47.07 -4.38 
Exosomes/Plasmid -32.650* 6.716 .001 -53.99 -11.31 
Bonferro
ni 
Cells PBS .175 6.716 1.000 -22.53 22.88 
Fugene/Plasmid 4.775 6.716 1.000 -17.93 27.48 
Fugene/Exosomes 3.675 6.716 1.000 -19.03 26.38 
Exosomes/Plasmid -3.250 6.716 1.000 -25.95 19.45 
Exosome/Plasmid/F
ugene 
29.400* 6.716 .005 6.70 52.10 
PBS Cells -.175 6.716 1.000 -22.88 22.53 
Fugene/Plasmid 4.600 6.716 1.000 -18.10 27.30 
Fugene/Exosomes 3.500 6.716 1.000 -19.20 26.20 
Exosomes/Plasmid -3.425 6.716 1.000 -26.13 19.28 
Exosome/Plasmid/F
ugene 
29.225* 6.716 .006 6.52 51.93 
Fugene/Plasmid Cells -4.775 6.716 1.000 -27.48 17.93 
PBS -4.600 6.716 1.000 -27.30 18.10 
Fugene/Exosomes -1.100 6.716 1.000 -23.80 21.60 
Exosomes/Plasmid -8.025 6.716 1.000 -30.73 14.68 
Exosome/Plasmid/F
ugene 
24.625* 6.716 .026 1.92 47.33 
Fugene/Exosomes Cells -3.675 6.716 1.000 -26.38 19.03 
PBS -3.500 6.716 1.000 -26.20 19.20 
Fugene/Plasmid 1.100 6.716 1.000 -21.60 23.80 
Exosomes/Plasmid -6.925 6.716 1.000 -29.63 15.78 
Exosome/Plasmid/F
ugene 
25.725* 6.716 .018 3.02 48.43 
Exosomes/Plasmid Cells 3.250 6.716 1.000 -19.45 25.95 
PBS 3.425 6.716 1.000 -19.28 26.13 
Fugene/Plasmid 8.025 6.716 1.000 -14.68 30.73 
Fugene/Exosomes 6.925 6.716 1.000 -15.78 29.63 
Exosome/Plasmid/F
ugene 





Cells -29.400* 6.716 .005 -52.10 -6.70 
PBS -29.225* 6.716 .006 -51.93 -6.52 
Fugene/Plasmid -24.625* 6.716 .026 -47.33 -1.92 
Fugene/Exosomes -25.725* 6.716 .018 -48.43 -3.02 
Exosomes/Plasmid -32.650* 6.716 .002 -55.35 -9.95 
 











Subset for alpha = 0.05 
1 2 
Tukey HSDa Exosome/Plasmid/Fugene 4 70.60  
Fugene/Plasmid 4  95.23 
Fugene/Exosomes 4  96.32 
PBS 4  99.83 
Cells 4  100.00 
Exosomes/Plasmid 4  103.25 
Sig.  1.000 .834 
 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 4.000. 
 
